PUBLISHED2 017 OUTCOMES OUTCOMES Cardiovascular Services OCHSNER Ochsner’s longstanding tradition of bringing physicians together to improve health outcomes continues today. Our goals are to work together with our referring providers to serve the needs of patients and to provide coordinated treatment through partnerships that put patients first. We have automated physician-to-physician patient care summaries for hospital encounters and enhanced the patient experience by giving patients the ability to schedule appointments online.
Close coordination and collaboration begin with transparency and access to the data you need to make informed decisions when advising your patients about care options. OchsnerOutcomes, a compilation of clinical data, represents only part of our efforts to better define the quality of Ochsner’s care and to share that information with you.
Trusted, independent organizations give the highest marks to Ochsner’s quality. Ochsner Medical Center was the only healthcare institution in Louisiana, Mississippi and Arkansas to receive national rankings in four adult specialties from U.S. News & World Report for 2017–2018. Ochsner Hospital for Children has been ranked among the top 50 children’s hospitals in the country for Cardiology Warner L. Thomas and Heart Surgery in the 2017–2018 U.S. News & World Report Best Children’s Hospitals rankings, President & making it the only nationally ranked children’s hospital in Louisiana. Chief Executive Officer ® Ochsner Health System Additionally, CareChex named Ochsner Medical Center, Ochsner Baptist and Ochsner Medical Center – West Bank Campus among the top 10% in the nation in Medical Excellence for 16 different specialties. Ochsner was also named #1 in the nation in Medical Excellence for Organ Transplants and, for the fifth year in a row, #1 in the nation in Medical Excellence and Patient Safety for Liver Transplant.
Ochsner is expanding its already robust research program with two new partnerships. The first, with TGen, brings early-phase cancer clinical trials to the region. The second, with TriNetX, an international data research network, will allow Ochsner clinicians to have the opportunity to provide new therapies to their patients sooner, as well as provide our researchers access to new tools with which to analyze data on our own patients and refine treatments.
Ochsner Multi-Organ Transplant Institute is one of 19 transplant hospitals in the United States to participate in the initial pilot phase of the Collaborative Innovation and Improvement Network Patient referrals, transfers and consults are critically important, Robert I. Hart, MD (COIIN) project, a three-year study by the United Network for Organ Sharing (UNOS) intended Executive Vice President & to increase transplantation, with a particular focus on utilization of deceased donor kidneys. and we want to make it easy for referring providers and their Chief Medical Officer staff. To refer your patient for a clinic appointment, call our Ochsner Health System Ochsner consistently earns the respect of independent evaluators. We do not rest on these achievements, but use them as a benchmark to continuously improve. We will continue to Clinic Concierge at 855.312.4190. share the data you need to care for your patients, provide services you may not have in your community and develop the collaborative relationships essential to ensuring the best outcomes for every patient, every time. Table of Contents
Letter from the Chairman ...... 6 John Ochsner Heart & Vascular Institute ...... 8 Advanced Heart Failure ...... 10 Heart Transplant ...... 10 Left Ventricular Assist Device (LVAD) Implantation . . . 14 Patient Survival After LVAD ...... 16 Pulmonary Hypertension ...... 20 Electrophysiology ...... 23 Interventional Cardiology ...... 26 Structural Heart and Valve Program ...... 32 Transcatheter Aortic Valve Replacement . . . . . 34 Adult Congenital Heart Disease Program . . . . 38 Noninvasive Cardiovascular Imaging ...... 41 Preventive Medicine and Cardiac Wellness . . . . . 42 Patient Experience ...... 50 Research ...... 54 Clinical Trials ...... 55 Publications ...... 59 Physician Team ...... 70 Contact Information and Locations ...... 71 About Ochsner Health System ...... 72 Letter from the Chairman
New solutions for chronic and To serve even more patients, we now complex cardiovascular problems offer same-day access and convenient online appointment scheduling. Our The John Ochsner Heart & Vascular patients have full access to their medical Institute (JOHVI) at Ochsner Medical records and can review all test results Center diagnoses and treats patients to maximize transparency. We have novel using the most advanced technologies programs for repairing failing coronary and outstanding subspecialty physician stents (brachytherapy), implanting expertise. As demonstrated in this leadless pacemakers, repairing aortic report, this translates to outstanding aneurysms with customizable grafts Christopher J. White outcomes for our patients. We’ve and preventing strokes without surgery MD, FSCAI, FACC, FAHA, FESC established a national and international by placing carotid stents. We remain Professor and Chairman of Medicine reputation for excellence in patient a national leader in treating patients The Ochsner Clinical School, care and innovation in technology and with advanced heart failure, and we are University of Queensland treatments. Over the years, we have been a second-opinion center for complex System Chairman of recognized by U.S. News & World Report, cardiovascular conditions. We are excited Cardiovascular Diseases CareChex® and Healthgrades® for our about all the potential benefits we will Medical Director, John Ochsner heart and vascular achievements. continue to offer patients throughout Heart & Vascular Institute the Gulf South. at Ochsner Medical Center Ochsner is the first and only medical center in our region to perform heart transplants, At JOHVI, we are eager to help our and the only center in Louisiana to offer referring physicians manage their the artificial heart and left ventricular assist patients’ most challenging diagnoses JOHN OCHSNER HEART & VASCULAR INSTITUTE devices (LVADs). and treatments. Through our advanced cardiovascular services, we strive to We were the first to perform heart valve restore patients’ health and improve replacement without surgery, and we their quality of life. continue to rank nationally with our high volume and low complication rates. We hope to become your trusted CARDIOVASCULAR SERVICES CARDIOVASCULAR
Our arrhythmia physicians offer new and partner in delivering the best possible | effective ablation procedures for ventricular cardiovascular care to your patients. tachycardia and atrial fibrillation. We offer the only Adult Congenital Heart Disease For information about the John Ochsner Program in the region, which serves adults Heart & Vascular Institute, visit us online
OUTCOMES who were diagnosed and treated for birth at Ochsner.org/heart or contact us defects of the heart as infants or children. by phone at 888.317.3717. We look We are constantly looking for new ways forward to hearing from you. to help our patients manage complex OCHSNER or ongoing cardiovascular problems. 6 7 John Ochsner Heart & Vascular Institute
The John Ochsner Heart & Vascular Institute offers state-of-the art diagnostic and leading-edge therapies for adult and pediatric cardiology patients in a program that is ranked among the top in the nation.
In 2016, Ochsner transitioned from ICD 9 to 10 (International While this tool permits greater specificity, the additional Statistical Classification of Diseases and Related Health Problems). classifications have resulted in outcomes metrics that may The 10th edition allows for greater accuracy with the addition of appear inconsistent from 2015 to 2016. more than 14,000 new diagnostic codes and subclassifications.
We have a team of experts available in: Overview of Subspecialties with Volume: Electrophysiology Cardiovascular Research • Device Clinic Volume – nearly • Mor e than 110 active cardiovascular • Advanced Heart Failure and Cardiac Transplantation Advanced Heart Failure and Cardiac Transplantation 12,000 device clinic assessments clinical research trials for investigational Ochsner is the only • Adult Congenital Heart Disease • Implanted Mechanical Assist Devices – 49 patients performed in 2016 therapies not available at other JOHN OCHSNER HEART & VASCULAR INSTITUTE health systems heart transplant center • Arrhythmia and Heart Rhythm Disorders • Heart Transplants – The only heart transplant center in • 265 pulmonary vein isolations (PVIs) Louisiana, performing 23 heart transplants in 2016 and for patients with AFib performed in Louisiana, performing • Cardiac PET Imaging Noninvasive Cardiovascular Imaging more than 900 throughout the history of the Ochsner in 2016 23 heart transplants • Cardiovascular MRI and CTA Imaging Services heart transplant program • Annually perform more than Interventional Cardiology 24,000 echo stress tests in 2016 and more than • Consultative Cardiology Consultative Cardiology 900 throughout the history CARDIOVASCULAR SERVICES CARDIOVASCULAR • Nearly 5,000 procedures performed • Annually perform more than
| • Heart and Vascular Surgery • Conducted more than 13,000 clinic visits annually in the cardiac catheterization laboratory 1,000 cardiac PET scans of the Ochsner heart • Interventional Cardiology and interpreted more than 76,000 EKGs annually • Annually perform more than transplant program. for the Ochsner system Heart Valve Program • Nonsurgical Heart Valve Replacement and Repair 5,400 vascular ultrasounds through • T ranscatheter Aortic Valve Replacement the Vascular Medicine department • Pediatric Cardiology (TAVR) – 191 cases in 2016 and more • Annually perform more than than 600 cases since 2011 • Pulmonary Hypertension 400 cardiac MRI tests that • Stroke Prevention and Carotid Stents • Minimally invasive mitral valve repair support referrals from the entire OCHSNER OUTCOMES Louisiana region • Vascular Medicine 8 9 ADVANCED HEART FAILURE
Keenen Shields Heart Transplant Heart Transplant Patient
Heart transplant patients at Ochsner have three-year survival rates higher than the Two days before Christmas 2014, Keenen Shields, a 24-year national average. In 2016, the three-year survival rate was 87.8 percent, compared veteran of the New Orleans Police to 85.1 percent nationally. Department, was on duty when he suffered his fourth heart attack. He experienced his first heart attack in 2006 and struggled with heart disease for eight years. He was admitted to Ochsner Medical Center in need of a heart transplant, and received his new heart on January 25, 2015. Now Keenen, a 53-year-old husband, father and grandfather of three, is embracing his second chance at life. In 2016, he participated in the Transplant Games of America. Keenen feels that competing in Ochsner Heart Transplant 1-Year Adult Patient Survival Hazard Ratio Ochsner the Games will get him “one step Comparison with Other Programs Other Programs closer to returning to the work Ochsner Medical Center Program Volume for Transplants, 7/1/2013 – 12/31/2015 I love – being a police officer.”
5.0
Worse ADVANCED HEART FAILURE CARDIOVASCULAR SERVICES CARDIOVASCULAR
2.0 |
1.0
0.5 The data reported here were prepared by the
OUTCOMES Better Scientific Registry of Transplant Recipients (SRTR) Estimated Hazard Ratio Hazard Estimated under contract with the Health Resources and 0.2 Services Administration (HRSA). Based on data available as of October 31, 2016. Publication date December 2016. OCHSNER 1 3 10 30 100 300 10 Program Volume 11 Ochsner’s Cardiomyopathy and Heart Transplant Program is the only Medicare-approved heart transplant program in Louisiana, performing over 20 heart transplants per year. It is also Louisiana’s only pediatric heart transplant program.
Ochsner Heart Transplant 3-Year Adult Patient Survival Hazard Ratio Ochsner Comparison with Other Programs Other Programs Ochsner Medical Center Program Volume for Transplants, 1/1/2011 – 6/30/2013
5.0
Worse ADVANCED HEART FAILURE CARDIOVASCULAR SERVICES CARDIOVASCULAR
2.0 |
1.0
0.5 The data reported here were prepared by the
OUTCOMES Better Scientific Registry of Transplant Recipients (SRTR) Estimated Hazard Ratio Hazard Estimated under contract with the Health Resources and 0.2 Services Administration (HRSA). Based on data available as of October 31, 2016. Publication date December 2016. OCHSNER 1 3 10 30 100 300 12 Program Volume 13 ADVANCED HEART FAILURE Left Ventricular Assist Device (LVAD) Implantation
The John Ochsner Heart & Vascular Institute (JOHVI) has been providing ventricular assist device (VAD) services for patients across the Gulf Coast region for over 20 years.
These devices help preserve the heart function of patients enhance the long-term VAD patient’s survival and quality of life. awaiting a heart transplant, otherwise known as a bridge At JOHVI, our team of seven advanced heart failure cardiologists to transplant, or as a permanent treatment option, known works closely with the patients’ primary cardiologist to share in as destination therapy. New technology and identification the management of patients with heart failure. of patients earlier in the heart failure disease process will
Adult Heart Transplants Heart Transplant & VAD Volume Pediatric Heart Transplants Ochsner Medical Center, 2000–2016 VADs 100%
52 2 45 43 52 80% 3 1 2
35 33 1 2 60% 28 22 2 5 2 5 ADVANCED HEART FAILURE
CARDIOVASCULAR SERVICES CARDIOVASCULAR 3
| 3 3 2 40% 6 3 10 3 15 32 30 29 27 26 10 26 27 8 6 24 20% 22 23
OUTCOMES 21 21 17 18 17 18 15
OCHSNER 0% 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 14 15 ADVANCED HEART FAILURE Patient Survival After LVAD
Ochsner’s vast array of advanced heart failure cardiologists, The experienced members of our VAD team also work closely VAD coordinators, heart failure coordinators, advanced in training emergency medical services providers in communities Indicators for referrals practice providers, pharmacists, social workers and support across the Gulf South and in neighborhoods where our VAD personnel work diligently with patients, their family members patients live. Our goal is to ensure local medical providers can for patients with advanced and referring providers in the ongoing care of patients after perform tests, discuss symptoms and consult with our specialists heart failure: implantation. These “shared care” partnerships contribute to determine if patients need additional care in a hospital setting greatly to the consistent success of Ochsner VAD patients or if modifications can be made at home to prevent a hospital • Class III/IV heart failure symptoms exceeding national standards in patient survival at the admission. At Ochsner, we have VAD coordinator and VAD one-year and three-year milestones. physician services on call 24 hours a day, seven days per week. • LVEF <35% • End-stage organ dysfunction • Hemodynamic instability • Hospitalization for heart failure *The Interagency Registry for Mechanically Assisted Circulatory Support is a registry in the past six months Ventricular Assist Devices (VADs) Overall Survival for patients who are receiving durable mechanical circulatory support device therapy Ochsner Medical Center, 2015–2016 to treat advanced heart failure. • Intolerance or withdrawal of oral agents 100% Ochsner | Intermacs* • Nonresponsive to CRT/BiV pacing
85.3% • Being considered for or currently 81.7% on inotropes 80% 71.8%
60.6% 60% ADVANCED HEART FAILURE CARDIOVASCULAR SERVICES CARDIOVASCULAR
| 40%
20%
OCHSNER OUTCOMES 0% 1-Year 3-Year 16 17 200%
*The Interagency Registry for Mechanically Assisted Circulatory Support is a registry Ventricular Assist Devices (VADs) Destination Therapy Survival for patients who are receiving durable mechanical circulatory support device therapy Ochsner Medical Center, 2015–2016 to treat advanced heart failure. 160%
Ochsner | Intermacs* 120%
84.0% 80% 76.8%
56.6% 53.4%
40%
0% 1-Year 3-Year
200%
*The Interagency Registry for Mechanically Assisted Circulatory Support is a registry Ventricular Assist Devices (VADs) Bridge to Transplant Survival for patients who are receiving durable mechanical circulatory support device therapy Ochsner Medical Center, 2015–2016 to treat advanced heart failure. 160%
Ochsner | Intermacs* 120% ADVANCED HEART FAILURE
CARDIOVASCULAR SERVICES CARDIOVASCULAR 86.0% 84.8%
| 80% 72.5% 66.1%
40% OUTCOMES
OCHSNER 0% 1-Year 3-Year 18 19 ADVANCED HEART FAILURE Pulmonary Hypertension
The Ochsner Pulmonary Hypertension Program is the largest in the region, caring for more than 450 patients and evaluating more than 250 patients for treatment options annually. The program’s team of cardiologists, pulmonologists, rheumatologists, radiologists, nurses, pharmacists and other providers work with each patient to develop an individualized treatment plan. Through this coordinated approach to care, patients will have access to care across the continuum including inpatient care, outpatient care, access to complex medical management, support groups, enhanced education and ADVANCED HEART FAILURE
CARDIOVASCULAR SERVICES CARDIOVASCULAR even lung transplantation if necessary.
| OUTCOMES OCHSNER
20 21 Electrophysiology
According to the American Heart Association, more than five million Americans have arrhythmias, with the most common being atrial fibrillation (AFib). Many are undiagnosed, and as the population ages and people live longer the incidence continues to rise. The risks for patients include increased risk for stroke and worsening heart failure and quality of life.
To meet the growing demand, Ochsner has added its sixth adult Cardiac Rhythm Management specialist and constructed its fourth dedicated Electrophysiology Lab. Along with two pediatric specialists, the John Ochsner Implantable technology, such as pacemakers and implantable Heart & Vascular Institute continues to lead the largest and cardioverter defribrillators (ICDs), continue to advance and serve as most comprehensive center for management of complex life-saving tools for managing a variety of heart rhythm disorders. arrhythmias and heart rhythm disorders in the Gulf South. Within the electrophysiology section, we have a robust team of device management specialists on site to provide in-person, remote web-based and telephonic management. Leading the Way in Ablation Therapy Conditions we treat: & Rhythm Disorders • Lead extractions Radiofrequency ablation is a nonsurgical, catheter-based therapy • Radiofrequency ablations for supraventricular arrhythmias designed to eliminate small pieces of heart tissue within the heart that create electrical dysfunction. At Ochsner, we work • Radiofrequency ablations for atrial fibrillation with cardiologists throughout the region to assist their patients • Radiofrequency ablations for ventricular tachycardia with complex AFib, ventricular tachycardia, supraventricular tachycardia and pulmonary vein isolation procedures. Furthermore, • Comprehensive evaluation for unexplained syncope through the Ochsner group practice, we have developed special Integrated Group Practice Units (IGPUs), where physicians from multiple disciplines come together to organize care around
CARDIOVASCULAR SERVICES CARDIOVASCULAR certain medical conditions. Placing the patient at the center
| of care, these providers develop team-based models that ensure the best course of therapy and outcomes for the patient. ELECTROPHYSIOLOGY A prime example, within the electrophysiology department, is the collaboration between electrophysiologists and structural heart specialists who manage patients with left atrial appendage OUTCOMES disease. This disease, if not corrected, results in a high risk for stroke-producing blood clots among patients with AFib. OCHSNER
22 23 400%
Radiofrequency Ablation / Pulmonary Vein Isolation Procedures Ochsner Medical Center, 2014–2016 320%
261
240%
175 160% 124
80%
0% 2014 2015 2016
1200%
Arrhythmia Procedures Ochsner Medical Center, 2016 960%
776 720% CARDIOVASCULAR SERVICES CARDIOVASCULAR
| 480% ELECTROPHYSIOLOGY
317 328
240% OUTCOMES
64
OCHSNER 0% Lead Extraction Pacemaker Implantable Cardioverter Defibrillator Ablation 24 25 The rate of in-hospital mortality among patients who had PCI procedures at Ochsner in 2016 was lower when compared to rates at similar hospitals. Our team includes national leaders from both the American College of Cardiology (ACC) and the Society for Cardiovascular Angiography and Interventions (SCAI), who are dedicated to the nonsurgical treatment and prevention of heart attack, stroke and limb loss.
PCI In-Hospital Risk-Adjusted Mortality Methodology and Source: American College of Cardiology – Interventional Cardiology Ochsner Medical Center, Q4 2015 – Q3 2016 National Cardiovascular Data Registry (ACC-NCDR) 2.5% Ochsner | U.S. Hospitals 50th Percentile The John Ochsner Heart & Vascular Institute is a regional referral center for complex, high-risk percutaneous coronary interventions (PCI). 2.0% 2.0% In 2016, nearly 5,000 cardiac catheterization procedures training in interventional coronary and peripheral vascular were performed by our expert team of adult and pediatric diseases. We also work with insurers and employer groups interventional cardiologists. Our interventional cardiologists for second opinions. 1.5%
are experts in coronary and peripheral interventions as well INTERVENTIONAL CARDIOLOGY as arterial and venous diseases. The range of services offered Advanced Interventional Cardiology Services: 1.2%
CARDIOVASCULAR SERVICES CARDIOVASCULAR goes from the carotid arteries to the feet with procedures
| • Brachytherapy ranging from diagnostic to advanced endovascular therapies. 1.0% The program offers the latest technology, including • PCI of chronic total occlusions (CTOs) brachytherapy, atherectomy, fractional flow reserve and intravascular ultrasound. Regionally, we collaborate with • TandemHeart and Impella implantation providers from across the Gulf South to offer high-risk • Paravalvular leak repair 0.5% angioplasty, including unprotected left main intervention and chronic total occlusions. We also take great pride • Carotid stenting in training tomorrow’s physicians through our ACGME- • Endovascular treatment for chronic limb ischemia 0.0% OCHSNER OUTCOMES accredited program, which includes eight fellows annually
26 27 In 2016, the rates for major vascular complications, including death, emergency coronary artery Use of fractional flow reserve (FFR) to validate lesions with stenosis between 40 and 70 percent is bypass grafting and stroke with PCI procedures, at John Ochsner Heart & Vascular Institute were a best practice measure to determine the appropriateness for PCI. At JOHVI, we use FFR at nearly far better than the rates at comparable hospitals. twice the rate of comparable hospitals. This is beneficial to patients because, with angiography alone, it is not always clear which narrowed area is most problematic. FFR offers a functional To serve these patients, our award-winning team has developed As national leaders in acute stroke prevention, we are experts innovative strategies to treat coronary heart disease, even in in carotid stenting and other cerebrovascular disease interventions. evaluation to confirm the PCI procedure will be effective or to guide the specialist to investigate people who have been told they have no options; renal artery And we are regional leaders in valvuloplasty, TAVR and limb other narrowed areas. stenosis and renovascular hypertension; chronic mesenteric salvage using the latest vascular rescue therapies for patients ischemia and peripheral arterial disease. with severe ischemia or complex wounds.
Any Adverse Event for PCI Methodology and Source: American College of Cardiology – FFR Utilization Methodology and Source: American College of Cardiology – Ochsner Medical Center, Q4 2015 – Q3 2016 National Cardiovascular Data Registry (ACC-NCDR) Ochsner Medical Center, Q4 2015 – Q3 2016 National Cardiovascular Data Registry (ACC-NCDR)
Ochsner | National Cardiovascular Data Registry Compare Group Ochsner | National Cardiovascular Data Registry Compare Group
8.0% 60%
6.9% 50.8% 6.4% 48%
4.9% 4.8% 36% INTERVENTIONAL CARDIOLOGY
27.0% CARDIOVASCULAR SERVICES CARDIOVASCULAR
| 3.2% 24%
1.6% 12%
0.0% 0% OCHSNER OUTCOMES
28 29 At Ochsner, our expert interventionalists pay particular attention to the management of fluoroscopy In 2016, John Ochsner Heart & Vascular Institute interventional agents and patient hydration during cardiac catheterization procedures to prevent acute kidney injury cardiologists performed more procedures using radial access. (AKI). At Ochsner, our patients are less likely to develop AKI versus those at comparable hospitals. Use of radial access has demonstrated reduced bleeding complications, lower readmission rates, fewer infections and shorter recovery times versus femoral access. The graph below shows a comparison between Ochsner 2016 data and the aggregate value for that metric across all U.S. patients in the National Cardiovascular Data Registry.
PCI In-Hospital Risk-Adjusted Acute Kidney Injury Methodology and Source: American College of Cardiology – Diagnostic Catheter Radial Access Site Methodology and Source: American College of Cardiology – Ochsner Medical Center, Q4 2015 – Q3 2016 National Cardiovascular Data Registry (ACC-NCDR) Ochsner Medical Center, 2016 National Cardiovascular Data Registry (ACC-NCDR)
Ochsner | U.S. Hospitals 50th Percentile Ochsner | National Cardiovascular Data Registry Compare Group
8.0% 80%
6.4% 64% 5.8%
5.0% 4.8% 48% 41.0% 40.6% INTERVENTIONAL CARDIOLOGY CARDIOVASCULAR SERVICES CARDIOVASCULAR
| 3.2% 32%
1.6% 16%
OCHSNER OUTCOMES 0.0% 0%
30 31 Structural Heart and Valve Program
The Structural Heart and Valve Program is unrivaled in the region,
and the Transcatheter Aortic Valve Replacement (TAVR) program STRUCTURAL HEART AND VALVE PROGRAM is recognized as having the best outcomes combined with one of the shortest lengths of stay in the United States.
TAVR is a procedure for select patients We launched our nonsurgical mitral
CARDIOVASCULAR SERVICES CARDIOVASCULAR ®
with severe symptomatic aortic stenosis valve repair program with MitraClip, | who are not candidates for traditional as well as multiple methods of left open chest surgery or are moderate atrial appendage closure. We take into and high-risk nonsurgical candidates. account the total patient, including TAVR uses a catheter to replace the heart frailty, lung function and patient wishes.
OUTCOMES valve instead of opening up the chest to We specialize in nonsurgical and remove the diseased valve. Since 2011, minimally invasive treatment. the Ochsner Structural Heart Team has performed over 600 TAVR procedures. OCHSNER
32 33 STRUCTURAL HEART AND VALVE PROGRAM
Transcatheter Aortic Valve Replacement
Since the inception of the TAVR program in 2010, Ochsner has become the regional leader in use of this specialized treatment for high-risk nonsurgical patients with aortic valve disease. More than 704 patients had this procedure at Ochsner with excellent outcomes and demonstrated quality of life improvement.
The Ochsner group practice integrated approach to patient-centered in one visit to enhance their patient experience. Services include multidisciplinary care is highly effective in its management all imaging studies, lab work and physician consultations with the of heart valve disease. Patients from across the Gulf South are necessary providers (i.e., interventional cardiology, cardiovascular seen in our outpatient Heart Valve Clinic and receive their full surgery, noninvasive cardiologist). medical evaluation, diagnostic workup and treatment plan
TAVR In-Hospital Mortality TAVR Length of Stay Ochsner Medical Center, Q3 2015 – Q2 2016 Ochsner Medical Center, Q3 2015 – Q2 2016
In 2016, 173 TAVR procedures Ochsner patients with TAVR STRUCTURAL HEART AND VALVE PROGRAM were performed at Ochsner. procedures had a hospital length 1.8 The In-Hospital Mortality Rate of stay averaging one day. was 0.8 percent. U.S. hospitals 1.6 Comparative hospitals performing performing at the 50th percentile at the 90th percentile achieved achieved a 1 percent mortality a length of stay of 1.6 days. CARDIOVASCULAR SERVICES CARDIOVASCULAR
| rate. Ochsner ranked among TAVR patients at Ochsner the best in the United States 1.0 enjoyed the benefit of returning 1.00 0.8 for In-Hospital Mortality. home sooner than those in 0.63 comparative hospitals.
Methodology and Source: American College Methodology and Source: American College of Cardiology – National Cardiovascular Data of Cardiology – National Cardiovascular Data 0.00 Registry (ACC-NCDR) Registry (ACC-NCDR) OCHSNER OUTCOMES Ochsner U.S. Hospitals 50th Percentile Ochsner U.S. Hospitals 90th Percentile
34 35 TAVR Stroke Complications Methodology and Source: American College of Cardiology – Ochsner Medical Center, Q3 2015 – Q2 2016 National Cardiovascular Data Registry (ACC-NCDR)
1.2
1.00
0.0 Ochsner U.S. Hospitals 50th Percentile
TAVR Access Site Complications Methodology and Source: American College of Cardiology – Ochsner Medical Center, Q3 2015 – Q2 2016 National Cardiovascular Data Registry (ACC-NCDR) STRUCTURAL HEART AND VALVE PROGRAM
3.3 CARDIOVASCULAR SERVICES CARDIOVASCULAR
|
1.00 0.8 OUTCOMES
OCHSNER Ochsner U.S. Hospitals 50th Percentile
36 37 STRUCTURAL HEART AND VALVE PROGRAM
The Adult Congenital Adult Congenital Heart Heart Disease Program is the only one in the Gulf Disease Program South treating congenital heart disease patients in Eighty-five percent of adult congenital heart disease patients an adult setting. have moderate to severe defects that have been repaired but not corrected. Lifelong monitoring before symptoms occur is essential. STRUCTURAL HEART AND VALVE PROGRAM
The Adult Congenital Heart Disease This team of dedicated professionals (ACHD) Program is the only one in the provided care for patients in both the Gulf South treating congenital heart hospital and clinic settings, including disease patients in an adult setting. The performing specialized procedures and
CARDIOVASCULAR SERVICES CARDIOVASCULAR team works hand in hand with referring supporting deliveries by mothers with
| physicians to provide care to patients congenital heart defects. The Ochsner with complex diseases. ACHD Program offers comprehensive care to adults with repaired or newly At the core of the program is the diagnosed congenital heart disease. collaboration between adult and pediatric OUTCOMES cardiovascular specialists, who are experts in managing congenital heart disease. OCHSNER
38 39 Noninvasive Cardiovascular Imaging
We offer the most broadly based, state-of-the-art cardiovascular imaging services in the Gulf South, including cardiac PET imaging and advanced echocardiography services, such as 3D transesophageal echo.
For cross-section imaging, we offer cardiac MRI services and We offer state-of-the-art cardiac PET imaging services, including computed tomography angiography. All noninvasive imaging stress myocardial perfusion with integration of absolute myocardial labs have achieved national certification through the Intersocietal flow, viability assessment and assessment of cardiac sarcoidosis. Accreditation Commission, ensuring high-quality patient care. We specialize in assessment of regional and global myocardial We often use multiple modalities to assess and diagnose complex ischemia in both straightforward and complex cases and assist problems. This is a strength that particularly benefits our adults in subsequent decisions for revascularization. We serve as the with congenital heart disease, structural heart disease and other major referral center in the Southeast for second opinions and highly complex cardiovascular diseases. These patients are often are also the site of several clinical trials. We are the only facility at a higher risk for irregular heartbeats, blood clots, congestive in the Southeast with the capabilities and experience to incorporate heart failure, heart attacks and even sudden cardiac death if they absolute myocardial flow into standard perfusion images such are not regularly monitored through multiple modalities. that subsequent decisions for revascularization can be achieved.
9500% Noninvasive Cardiovascular Imaging 2015 Ochsner Medical Center, 2015–2016 2016
7600% NONINVASIVE CARDIOVASCULAR IMAGING 24,291 23,373
5700% 5,441 5,268 CARDIOVASCULAR SERVICES CARDIOVASCULAR
| 3800%
1900% OUTCOMES 953 935 680 330 403 466
OCHSNER 0% PET MRI Vascular Echo Spect 40 41 Preventive Medicine and Cardiac Wellness
Ochsner’s Cardiac Rehabilitation Program is professionally supervised to help patients recover from heart attacks, heart surgery and percutaneous coronary intervention procedures.
Patients begin rehabilitation while they are in the hospital. plans to exercise programs. Once a patient completes the Once discharged, patients are enrolled in a 12-week monitored process, they are encouraged to continue their own cardiac rehabilitation program that includes everything from diet rehabilitation and make routine appointments at our center.
Quality of Life Metrics Ochsner Medical Center, 2016 higher number indicates improvement
Pre | Post
120% +13% 111.6
99.0 PREVENTIVE MEDICINE AND CARDIAC WELLNESS 96%
72% CARDIOVASCULAR SERVICES CARDIOVASCULAR
| 48%
+10% 24.5 24% 22.4 +20% OUTCOMES 16.4 13.6 +12% 7.8 8.8
OCHSNER 0% Physical Function Energy/Fatigue Pain Total QoL 42 43 Behavioral Metrics: Mean Ochsner Medical Center, 2016 lower number indicates improvement 11.2%
Pre | Post 8.4% −24% 7.5
5.7 5.6% −20% 4.6 −27% 4.1 3.7 −28% 3.0 3.0 2.8% 2.2
0.0% Anxiety Depression Hostility Somatization
50%
Behavioral Metrics: Categorical PREVENTIVE MEDICINE AND CARDIAC WELLNESS Ochsner Medical Center, 2016 40%
Pre | Post 30% −19% −18% 22 CARDIOVASCULAR SERVICES CARDIOVASCULAR
21 | 20% 18 17 −40% 10 10% OUTCOMES 6
OCHSNER 0% Anxiety Depression Hostility 44 45 Inflammation Ochsner Medical Center, 2016 12.8%
Pre | Post 9.6% −47% 7.6
6.4%
4.0 3.2%
Lipid Metrics Ochsner Medical Center, 2016 0.0% hs-CRP Pre | Post
155% 60% −1% 137 136
Anthropometrics PREVENTIVE MEDICINE AND CARDIAC WELLNESS −7% Ochsner Medical Center, 2016 124% 118 48% 110 Pre | Post 93% 36% −3% −1% 29.6 29.4 73 71
CARDIOVASCULAR SERVICES CARDIOVASCULAR −6%
| 62% 24% 23.1 +5% 21.8 41 43
31% 12% −3% 3.5 3.3
OCHSNER OUTCOMES 0% 0% Total Cholesterol HDL-C LDL-C Triglycerides TC/HDL BMI % Body Fat 46 47 40%
Exercise Metrics Ochsner Medical Center, 2016 32%
Pre | Post 24% +9% 19.7 18.1 +25% 16% 14.8 11.8
8%
0% Peak VO2 Heart Rate Recovery
Exercise Metrics: Heart Rate Recovery PREVENTIVE MEDICINE AND CARDIAC WELLNESS Ochsner Medical Center, 2016
Normal | Abnormal CARDIOVASCULAR SERVICES CARDIOVASCULAR
| 44% 45% 56% 55% OUTCOMES
OCHSNER Pre Post 48 49 Patient Experience Ochsner Clinic and the John Ochsner Heart & Vascular Institute are committed to delivering excellent clinical CARDIOVASCULAR SERVICES CARDIOVASCULAR
| outcomes while ensuring patients and their families receive PATIENT EXPERIENCE the best overall experience in the process. We believe in transparency and seek feedback from our patients in efforts to improve our clinical care and patient experience opportunities. OCHSNER OUTCOMES
50 51 Patient feedback based on results submitted to the Clinician and Group Consumer Assessment Patient feedback based on national survey results of discharged patients for 2016 from all of Healthcare Providers and Systems (CGCAHPS) database from all U.S. reporting medical U.S. hospitals medicare.gov/hospitalcompare. practices in 2016.
Cardiology – Clinician and Group Consumer Assessment Cardiology – Hospital Consumer Assessment CGCAHPS information was based on provider specialty The HCAHPS data was based on the specialty field in infoEdge for patients with of Healthcare Providers and Systems (CGCAHPS) with a visit date between 1/1/2016 – 12/31/2016; adjusted of Healthcare Providers and Systems (HCAHPS) a discharge date between 1/1/2016 – 12/31/2016. The specialty field is based on the Ochsner Heart & Vascular Institute, 2016 per Press Ganey methodology for eSurvey. Ochsner Heart & Vascular Institute, 2016 DRG that is on the record and the CMS specialty group that is tied to the DRG.
Ochsner Average | Press Ganey Average Ochsner Average | Press Ganey Average
100% 100% 95.0 95.5 96.1 92.9 90.8 92.6 86.7 87.8 87.6 82.7 84.0 80.1 80.3 81.3 80% 78.6 80% 73.9 73.4 73.1 71.1 67.9 67.6 66.6 63.5 65.4 64.9 60.3 60% 60% 55.9 54.1 CARDIOVASCULAR SERVICES CARDIOVASCULAR
| 40% 40% PATIENT EXPERIENCE
20% 20%
OCHSNER OUTCOMES 0% 0% Recommend this Physician Office Staff Access Care Overall Hospital Comm Response of Comm Hospital Pain Comm about Discharge Care Provider Office Communication Quality to Care Coordination Rating with Nurses Hospital Staff with Docs Environment Management Medicines Information Transitions 52 53 RESEARCH LIFE: This study is evaluating the benefits of LCZ696 (an approved drug for Heart Failure that combines sacubitril and valsartan) when compared to valsartan alone in the Clinical Trials management of heart failure symptoms in patients diagnosed with CHF class IV or patients receiving ongoing inotrope Heart Failure infusion therapy.
DREAM HF: This study is evaluating the benefits of stem cells OAR: This registry observes the clinical long-term management vs placebo in heart failure patients with left ventricular systolic and outcomes of heart transplant recipients with the regular dysfunction that are on maximum, optimized, medical therapy. use of AlloMap testing. The AlloMap blood test is intended The stem cells are injected directly into the cardiac muscle during to help determine if a heart transplant recipient has a low a cath lab procedure. The aim of the study is to repair damaged probability of acute rejection at the time of testing. This test, heart tissue and reduce overall heart failure symptoms. first commercially introduced in 2005, identifies the expression of genes on white blood cells that circulate in the blood and Fire HF: The purpose of this study is to see if Injectafer® cause the heart to be rejected. is efficient and safe to improve quality of life, reduce death, and lower hospitalizations associated with heart failure. THAOS: This is an observational survey open to all patients with Transthyretin-associated amyloidosis, including both inherited GRAHF 2: The goal of this trial is to determine if genetic testing and wild type disease and participants with TTR mutations can determine which African American patients will respond to without a diagnosis of ATTR. Because transthyretin-associated Bidil treatment for heart failure. African American patients with a amyloidosis is very rare, there are many unanswered questions reduced ejection fraction are followed for two years while taking about this disease. In order to understand the disease better Bidil to determine the status of heart failure symptoms and heart and improve the care of patients, the Transthyretin-Associated Research failure functional class while on this medication. Amyloidosis Outcome Survey (THAOS) was created. PATISIRAN: This study is an expanded access protocol which allows patients with polyneuropathy associated with hATTR Consultative At any given time, more The John Ochsner Heart & Vascular Institute research program amyloidosis to receive a study drug called Parisian. ADAPTABLE: This is a three-year pragmatic clinical trial that than 60 clinical trials are comprises a unique group of individuals dedicated to providing will compare the effectiveness of two different daily doses INVESTED: The INVESTED trial is designed to determine which actively enrolling patients clinical research opportunities to our patients. of two formulations of influenza vaccine, the standard dose of aspirin widely used to prevent heart attacks and strokes across the spectrum of or an investigational higher dose, is more effective in reducing in individuals living with heart disease. Ochsner is using Epic CARDIOVASCULAR SERVICES CARDIOVASCULAR
In general, clinical trials are used to test the At any given time, more than 60 clinical notifications to help cardiologists identify patients for this | deaths and heart– or lung-related admissions to the hospital. conditions in the cardiology safety and effectiveness of drugs, devices trials are actively enrolling patients across The targeted population for this study is individuals with a PCORI study. This has allowed the research team to reach research program. and medical procedures in the human the spectrum of conditions in the cardiology history of heart attack within one year, or heart failure patients patients at several locations. population. This ongoing collaboration research program. More than 1,500 patients with at least one hospitalization within the past two years. between physician investigators and study are enrolled in over 100 trials.
volunteers is one of the foundations of RESEARCH modern healthcare because clinical trials help set the standards for patient care. OCHSNER OUTCOMES
54 55 PARADISE: The purpose of this study is to test if LCZ696 complications rate through one-month post MRI scan in RESPOND CAS: The objective of this continued access study Interventional (Entresto) taken twice a day, compared to ramipril taken twice subjects who undergo a clinically indicated MRI scan according is to gather confirmatory evidence on the safety of the SonRtip a day, is safe and effective in reducing complications following to the MRI Conditions of Use. lead and performance of the automatic atrioventricular (AV) AMULET: The purpose of the AMULET study is to determine an acute myocardial infarction (heart attack), such as death delay and interventricular (VV) delay optimization algorithm if the Amulet device is a safe and effective option for left atrial from cardiovascular causes, hospitalization for heart failure , EnSite: The EnSite Precision Observational Study is looking to used in the PARADYM RF SONR Cardiac Resynchronization appendage closure when compared to the Watchman device. or outpatient heart failure. characterize the usage of the EnSite Precision Cardiac Mapping Therapy with Defibrillation (CRT-D) device (Model 9770) in System and its unique features in a real world cardiac ablation a patient population that is reflective of current heart failure BEST-CLI: A study to evaluate the effectiveness of the best TELEX: This study hopes to Establish whether the angiotensin environment. treatment practice. endovascular compared to best surgical revascularization in receptor blocker (ARB) telmisartan improves walking performance patients with chronic limb ischemia. Subjects must be eligible in people with peripheral artery disease (PAD), a condition in LEADLESS II: The intent of this study is to evaluate the safety UNTOUCHED: The primary aim of the study is to estimate the to undergo both endovascular therapy and surgical bypass in which cholesterol blockages in the leg arteries prevent blood from and effectiveness of the implanted Nanostim Leadless Pacemaker rate and causes of shocks in patients suffering from severely order to qualify for the trial. CLI is defined as arterial insufficiency getting down to the legs and feet during exercise. It also aims to for treatment of bradycardia in a subject population indicated for reduced cardiac function, who have been implanted with the with gangrene, non-healing ischemic ulcer, or rest pain consistent determine whether telmisartan plus supervised exercise improves a single wire pacemaker. Emblem S-ICD System. The results will allow physicians to take with Rutherford categories 4–6. walking performance more than telmisartan alone and more than appropriate measures for primary prevention of sudden cardiac supervised treadmill exercise alone. Left Atrial Transport Function Following Cryoballoon PVI: arrest (SCA) in such patients. The S-ICD system can be placed CADLAD: This trial utilizes passive tomography to identify Patients undergoing pulmonary vein isolation for atrial fibrillation just under the skin and provides the patient with the same significant coronary artery disease without an invasive procedure. with cryoballoon. Impact of procedure on the left atrium of the protection from cardiac arrests as Trans venous-ICDs. However, The primary objective is to show that the technology can identify Electrophysiology heart is compared using pre- and post-procedure MRI scans. it leaves the heart and vasculature untouched thus minimizing coronary blockage as well as the current “gold standard” the risk of complications associated with TV-ICDs. of angiography. AdaptResponse: This trial compares electrical treatment MultiPoint Pacing Post Market Study (MPP PMS): between standard device programming and adaptive Evaluating real-world use of MPP technology in patients CALM II: This study looks at reshaping the carotid sinus by resynchronization therapy programming in patients with indicated for a cardiac resynchronization therapy (CRT) device. Cardiothoracic Surgery implanting the MobiusHD device into the carotids. The goal newly implanted, Medtronic CRT devices. This is a prospective, multicenter, non-randomized registry/ of the trial is to control patients with treatment resistant observational study enrolling up to 2000 patients with MOMENTUM 3 CAP (HeartMate III): Comparison of the hypertension through reducing strain on the baroreceptors. aMAZE: The aim of this study is to determine if the combination successful Abbott (formerly SJM) CRT MP device implant. HeartMate III LVAD to the HeartMate II LVAD. The HeartMate The CALM II protocol is a follow-up of the CALM clinical trial. of two non-surgical treatments (pulmonary vein isolation (PVI) III data shows decreased bleeding events and no pump related The CALM study was a “First in Man” safety study in which and closure of the left atrial appendage utilizing the LARIAT Optimizer IVs Studies: Ochsner is participating in four thrombosis. The smaller size of the HeartMate III pump allows only 8 sites, including Ochsner, were asked to participate. procedure) may treat persistent and/or longstanding persistent Optimizer studies. These studies assess the different for implantation in a greater population of patients. atrial fibrillation more effectively than PVI alone. generations of the Optimizer IVs systems which are used to CREST II: The purpose of this study is to compare carotid artery treat heart failure. The device is an implantable that is similar PREVENT II: This is a double-blind placebo-controlled study disease treatment options. The study consists of three options: BEAT HF (Barostim): The Barostim implantable device to a pacemaker; however, the Optimizer IVs does not initiate for subjects receiving the HeartMate II LVAD. Subjects will be carotid endarterectomy plus intense medical therapy, carotid stimulates the baroreceptors in an effort to improve blood a new heartbeat or change the heart rate. The device uses a randomized to receive warfarin + placebo in the treatment arm artery stenting plus intense medical therapy, medical therapy flow to the heart, kidneys and blood vessels in patients with therapy called Cardiac Contractility Modulation which improves or warfarin + aspirin in the control arm. This is to determine if alone. The overall goal of the study is to prove if intervention CARDIOVASCULAR SERVICES CARDIOVASCULAR
heart failure. The goals of the study are to improve overall the pumping function of the heart. subjects in the treatment arm experience a reduced incidence
| is more effective than medical therapy alone, and if so, which heart failure symptoms and the quality of life for those with of bleeding without an increased risk in thromboembolic events. intervention produces better outcomes. (Vascular surgery/ an advanced heart failure diagnosis. QPE-EXCELS: The purpose of this study is to confirm long- Interventional) term safety of the BIOTRONIK Sentus QP lead used with the SynCardia 50cc TAH-t (total artificial heart): The SynCardia BRADY MRI PAS: The primary objective of this study is to BIOTRONIK CRT-D device. The Sentus QP lead may offer more TAH-t 50cc provides circulatory support in bridge-to transplant
evaluate the long-term safety of the Tendril MRI lead implanted possibilities for locating a stable and optimal position during patients with biventricular heart failure. The 50cc version of RESEARCH with a SJM Brady MRI System in subjects with a standard lead placement, thus potentially avoiding/reducing future the device is smaller than the FDA approved TAH-t 70cc model, bradycardia pacing indication through 60 months of follow surgical interventions. and thus can be used for children and adults with smaller up. Additionally, this study will evaluate the MRI scan related chest cavities. OCHSNER OUTCOMES
56 57 cVAD Registry: The Global cVAD Registry is an observational, REDUCE II: The goal of this trial is to improve the quality of life RESEARCH multicenter, retrospective records review of patients receiving the in patients with diastolic heart failure with a preserved ejection Arena R, Lavie CJ, Cahalin LP, Briggs PD, Guizilini S, Daugherty Impella devices in the daily, routine clinical care per institutional fraction. The study uses the IASD device to shunt blood flow J, Chan WM, Borghi-Silva A. Transforming cardiac rehabilitation standards and treating physician’s discretion. In order to best from left atrium to the right atrium and potentially lowers left into broad-based healthy lifestyle programs to combat represent real-world practice, patients receiving the Impella atrial pressure. This is a non-surgical, interventional procedure Publications noncommunicable disease. Expert Rev Cardiovasc Ther 2016; devices will be included in the registry without pre-selection. in which a small opening is created in the wall between the 14(1): 23–26. atria. The device is inserted into the opening to keep it open Abdelghani SA, Rosenthal TM, Morin DP. Surface EARLY TAVR: The purpose of this study is to determine over time. The primary objective is to show a reduction in Electrocardiogram Predictors of Sudden Cardiac Arrest. Arena R, Lavie CJ, Hibert MF, Williams MA, Briggs PD, whether transcatheter aortic valve replacement is helpful for left atrial pressure and an improved quality of life through Ochsner J Fall; 16(3): 280–9, 2016. Guazzi M. Who will deliver comprehensive healthy lifestyle patients who have severe, calcific, aortic stenosis, but do not reduction in shortness of breath. interventions to combat non-communicable disease? have symptoms. Abi-Samra F, Gutterman D: Cardiac contractility modulation: Introducing the healthy lifestyle practitioner discipline. Pulmonary Hypertension a novel approach for the treatment of heart failure. Heart Fail Expert Rev Cardiovasc Ther 2016; 14(1): 15–22. ECLIPSE: The purpose of this trial is to evaluate orbital Rev, Nov 21(6): 645–660, 2016. atherectomy vessel preparation using the The Diamondback Armstrong EJ, Chhatriwalla A, Szelip M, Swainathan RV, Patel Escalate: Escalate is an investigator sponsored study that 360® Coronary Orbital Atherectomy System (OAS) when Adams KF Jr, Butler J, Patterson JH, Gatti Stought W, Bauman RAG. Late Breaking Trials of 2015 in Structural Heart Disease evaluates the drug combination therapy of Abmrisentan compared to standard angioplasty prior to placing a stent JL, van Vedlhuisen FJ, Schwartz TA, Sabbah H, Mackowiak JI, and Peripheral Artery Disease: Commentary Covering ACC, and Tadalafil in liver transplant candidates with pulmonary for the treatment of coronary artery disease. Ventura HO, Ghali JK. Dose response characterization of the EuroPCR, SCAI, TCT, VIVA ESC, and AHA. Catheter Cardiovasc hypertension. While this drug combination is often used association of serum digoxin concentration with mortality Interv. 2016. May; 87(6): 1020–1026. to help control pulmonary hypertension in those waiting FMD Registry: This registry hopes to assist in determining the outcomes in the Digitalis Investigation Group trial. Eur J Heart liver transplant, the effectiveness of the outcomes has little natural course of fibromuscular dysplasia and identifying which Fail. 2016 Aug; 18(8): 1072–81. Aronow HD, Collins TJ, Gray WA, Jaff MR, Kluck BW, Safian RD, documentation. The primary outcome of the study is to procedures are more effective to relieve symptoms and reduce Sobieszczyk PS, Wayangankar SA, White CJ. Core Curriculum. show that this particular treatment is successful in reducing adverse outcomes. Alpert MA, Lavie CJ, Agrawal H, Kumar A, Kumar SA. Cardiac SCAI/SVM Expert consensus statement on carotid stenting: pulmonary atrial pressures after two months of therapy. effects of obesity: PATHOPHYSIOLOGIC, CLINICAL, AND Training and credentialing for carotid stenting. Catheter PARTNER 3: This is a randomized, controlled study to establish PROGNOSTIC CONSEQUENCES-A REVIEW. J Cardiopulm Cardiovasc Interv. 2016; 87(2): 188–199. Soprano: This is a double blind randomized study to assess the safety and effectiveness of the SAPIEN 3 transcatheter Rehabil Prev 2016 Jan–Feb; 36(1): 1–11. the efficacy and safety of macitentan for the treatment heart valve in low risk patients who have severe, calcific aortic Asim Rafique A, Chandrasekhar J, Baber U, Sartori S, Aquino M, of pulmonary hypertension in patients with an LVAD (left stenosis requiring aortic valve replacement. (The study is only Amin AP, Wang TY, McCoy L, Bach RG, Effron MB, Peterson Kapadia S, Rao S, Muhlestein JB, Toma C, Strauss C, Weintraub W, ventricular assist device). enrolling valve-in-valve patients at this time) ED, Cohen DJ. Impact of Bleeding on Quality of Life in Patients Weiss S, DeFranco A, Pocock S, Effron M, Keller S, Baker B, Kini A, on DAPT: Insights From TRANSLATE-ACS. J Am Coll Cardiol Mehran R, Henry T. Prevalence of prasugrel use and associations SPHERE: This is a prospective observational drug registry being Portico TAVR: St. Jude’s Portico aortic valve allows for trans- 2016; 67(1): 59–65. between type of acute coronary syndrome and 1-year clinical conducted in order to further outline the clinical characteristics, aortic valve replacement in high, extreme-risk surgical patients. outcomes. J Am Coll Cardiol 2016; 68 (Suppl 1): B42. outcomes and dosing/titration regiments of patients treated Archer E, Thomas DM, McDonald SM, Pavela G, Lavie CJ, Hill with Uptravi in patients with pulmonary hypertension. RADIANCE: This study’s aim is to show safety and efficacy of JO, Blair SN. The validity of US nutritional surveillance: USDA’s Ayakannu Yamini, Benjo Alexandre M, White Christopher,
CARDIOVASCULAR SERVICES CARDIOVASCULAR loss-adjusted food availability data series 1971–2010. Curr Probl renal denervation using the Paradise System for patients with Patel Rajan, Altabaqchali Sayf, El-Hayek Georges. The elephant | uncontrolled HTN. Ochsner is the 3rd highest enrolling site, Cardiol 2016 Nov–Dec; 41(11–12): 268–292. in the room: The increased incidence of neurological deficits and the sponsor utilizes a Facebook study recruitment app with carotid endarterectomy vs protected carotid stenting which has referred several new patients to the Ochsner system. Arena R, Daugherty J, Bond S, Lavie CJ, Phillips S, Borghi-Silva in randomized controlled trials. Ochsner’s Thirteenth Annual A. The combination of obesity and hypertension: a highly Research Day 2016.
unfavorable phenotype requiring attention. Curr Opin Cardiol RESEARCH 2016 Jul; 31(4): 394–401. OCHSNER OUTCOMES
58 59 Ayakannu Yamini, Benjo Alexandre, White Christopher, Bhatheja S, Panchal HB, Ventura H, Paul TK. Obesity Chandrasekhar J, Baber U, Sartori S, Aquino M, Faggioni M, Davidson T, Ricketts A, Sui X, Lavie CJ, Blair SN, Ross R. Patel Rajan, Altabaqchali Sayf, El-Hayek Georges. Long-term cardiomyopathy: pathophysiologic factors and nosoloic Vogel B, Farhan M, Muhlestein JB, Strauss C, Toma C, Weintraub Cardiorespiratory fitness within an obesity risk classification follow-up metaanalysis of carotid stenting vs endarterectomy: reevaluation. Am J Med Sci 2016 Aug; 352(2): 219–22. W, Weiss S, DeFranco A, Kini A, Effron M, Baker B, Keller S, model identifies men at increased risk of mortality: 304 board different procedures with a similar safety profile. Ochsner’s Kapadia S, Pocock S, Rao S, Mehran M. Relationship between #141 June 1, 9:30 AM – 11:00 AM. Med Sci Sports Exerc Thirteenth Annual Research Day 2016. Bienvenu L, White CJ. Development and Implementation of a anemia, prasugrel use and clinical outcomes in contemporary 2016 May; 48(5 Suppl 1): 75. Quality Improvement process for Echocardiographic Laboratory percutaneous coronary intervention for acute coronary Bae JP, Faries DE, Ernst FR, Lipkin C, Zhao Z, Moretz C, Accreditation. Echocardiography 2016 Mar; 33(3): 459–71. syndromes. J Am Coll Cardiol 2016; 68 (Suppl 1): B44–B45. De Lemos J, Kiernan F, Lavie C, Thompson P. Secondary Lieu HD, Effron MB. Comparative resource utilization and prevention after acute coronary syndrome. The Medical costs for patients with acute coronary syndrome managed Bober RM, Thompson C, Morin DP. The Effect of Coronary Chandrasekhar J, Baber U, Sartori S, Aquino M, Henry T, Rao Roundtable Cardiovascular Edition, 2016. with percutaneous coronary intervention and treated with Revascularization on Myocardial Blood Flow as Assessed by Stress S, Snyder C, Weintraub W, Effron M, Pocock S, Keller S, Kini A, clopidogrel or prasugrel. Am J Health Syst Pharm 2016; Positron Emission Tomography. J Nucl Cardiol Mar 28, 2016. Strauss C, Mehran R, Kapadia S. Impact and use of prasugrel De Schutter A, Kachur S, Lavie CJ, Boddepalli RS, Patel DA, 73(6): 395–403. versus Clopidogrel as a function of age among patients with Milani RV. The impact of inflammation on the obesity paradox Bober RM, Thompson CD, Morin DP. The effect of coronary acute coronary syndrome undergoing percutaneous coronary in coronary heart disease. Int J Obes (Lond) 2016 Jul 25 Bansal A, Bhama JK, Patel R, Desai S, Mandras SA, Patel H, revascularization on regional myocardial blood flow as assessed by intervention. Eur Heart J 2016; 37: (Abstract Supplement) 1164. doi:10.1038/ijo2016.125. Collins T, Reilly, JP, Ventura HO, Parrino PE. Using the minimally stress positron emission tomography. J Nucl Cardiol 2016 Mar 28. invasive impella 5.0 via the right subclavian artery cutdown Chandrasekhar J, Baber U, Sartori1 S, Rao S, Henry T, De Schutter A, Lavie CJ, Kachur S, Jahangir E, Menezes A, for acute on chronic decompensated heart failure as a bridge Breneman CB, Polinski K, Sarzynski MA, Lavie CJ, Kokkinos PF, Weintraub W, Effron M, Danias G, Keller S, Weiss S, Defranco Dinshaw H, Shum K, Arena R, Milani R. Variations in response to decision. The Ochsner Journal, 2016 Fall; 16(3): 257–262. Ahmed A, Sui X. The impact of cardiorespiratory fitnessAm J A, Muhlestein JB, Kapadia, Pocock S, Mehran R , The impact to cardiac rehabilitation and outcomes. Ochsner Journal Med 2016 Jun 8 pii: S0002–9343(16) 30550–2. of DAPT clinical risk score and ACUITY bleeding risk score in 2016; 16(3): 362. Bansal, Aditya, Bhama, Jay K., Patel, Rajan, Desai, Sapna, determining adverse clinical outcomes following PCI: results Mandras, Stacy A., Patel, Hamang, Collins, Tyrone, Reilly, John Brooks GC, Lee BK, Rao R, Lin F, Morin DP, Zweibel SL, from the PROMETHEUS study. Eur Heart J 2016; 37: (Abstract Domercant J, Polin N, Jahangir E. Cardio-Oncology: A Focused P., Ventura, Hector, Parrino, Eugene P. Using the Minimally Buxton AE, Pletcher MJ, Vittinghoff E, Olgin JE on behalf Supplement) 214. Review of Anthracycline Human Epidermal Growth Factor Invasive Impella 5.0 via the Right Subclavian Artery Cutdown of the PREDICTS investigators. Predicting persistent left Receptor 2 Inhibitor and Radiation-Induced Cardiotoxicity and for Acute on Chronic Decompensated Heart Failure as a Bridge ventricular dysfunction following myocardial infarction: From Chong-Yik R, Bennett AL, Milani RV, Morin DP. Telemetry Management. Ochsner Journal 2016 Fall; 16(3): 250–6. to Decision. Ochsner J. 2016; 16(3): 210–216. the PREDiction of ICd Treatment Study (PREDICTS). J Am Coll Overuse and Its Economic. Implications. Poster presentation, Cardiol. March 15; 67(10): 1186–96, 2016. American College of Cardiology Scientific Sessions, 2016. Donnarumma E, Ali MJ, Rushing AM, Scarborough AL, Bradley Benjo A, Cardoso RN, Collins T, Garcia D, Macedo FY, El-Hayek Poster presentation, Ochsner Research Day, 2016 (First prize, JM, Organ CL, Islam KN, Polhemus DJ, Evangelista S, Cirino G, G, Nadkarni G, Aziz E, Jenkins JS. Vascular brachytherapy versus Bsbu AS, Arena R, Myers J, Padmakumar R, Maiya AG, Cahalin Ochsner Medical Foundation Resident/Fellow Research Jenkins JS, Patel RA, Lefer DJ, Goodchild TT. Zofenopril protects drug-eluting stents in the treatment of in-stent restenosis: LP, Waxman AB, Lavie CJ. Exercise intolerance in pulmonary Competition, Dr. Chong-Yik). against myocardial ischemia-reperfusion injury by increasing A meta-analysis of long-term outcomes. Catheter Cardiovasc hypertension: mechanism, evaluation and clinical implications. nitric oxide and hydrogen sulfide bioavailability. J Am Heart Interv. 2016; 87(2): 200–208. Expert Rev Respir Med 2016 Sep; 10(9): 979–90. Church T, Lavie C, O’Keefe J, Arena R. The role of physical Assoc. 2016; 5(7). fitness in cardiovascular disease prevention. The Medical Bennett A, Pfeffer M, Thai S, Baetz B, Campbell P, Patel H, Campbell PT, Krim SR, Nguyen T, Eng, M, Wei Y, Van Tran H, Roundtable Cardiovascular Edition, 2016. Douglas PS, Cerqueira MD, Berman DS, Chinnaiyan K, Cohen CARDIOVASCULAR SERVICES CARDIOVASCULAR
Eiswirth C, Ventura H, Krim S. Triple Antithrombotic Therapy Ventura HO. Acute decompensated and chronic stage D heart MS, Lundbye JB, Patel RAG, Sengupta PP, Soman P, Weissman | in Patients with Left Ventricular Assist Devices: A Single Center failure: 4th Edition of Management Complex of CV Problems. Church TS, Lavie CJ, Sarznyski MA, Swift DL. Exercise and NJ. The Future of Cardiovascular Imaging: Report of a Think Experience. J Heart Lung Transplant. 2016; 35(4): S250–S251. Blackwell Publishing. 169–197, 2016. lipids. In: Ballantyne CM, ed. Clinical Lipidology: A Companion Tank Convened by the American College of Cardiology. to Braunwald’s Heart Disease. Philadelphia, PA: Elsevier; J American Coll Cardiol. 2016. Bernard ML: Pacing Without Wires: Leadless Cardiac Pacing. Cavar M, Ljubkovic M, Bulat C, Bakovic D, Fabijanic D, Kr5aljevic 2015: 210–216.
Ochsner Journal, Fall 16(3): 238–42, 2016. J, Karanovic N, Dujic Z, Lavie CJ. Trimetazidine does not alter Edward JA, Mandras S. An Update on the Management RESEARCH metabolic substrate oxidation in cardiac mitochondria of target Collins, T.J. (2016) Catheter-Based Thrombectomy and of Chronic Thromboembolic Pulmonary Hypertension. patient population. Br J Pharmacol 2016 May; 173(9): 1529–40. Thrombolysis: Case Examples. In: Handbook of Interventions for Curr Probl Cardiol. 2017 Janl42(1):7-38. doi: 10.1016/j. Structural Heart and Peripheral Vascular Disease, 1st Edition, 2016. cpcardiol.2016.11.001. OCHSNER OUTCOMES Jaypee Brothers Medical Publishers, New Delhi, Ch 18 pp. 243–265. 60 61 Effron M, Baber U, Keller S, Weintraub W, Henry T, Kapadia Faselis C, Kokkinos P, Tsimploulis A, Pittaras A, Myers J, Lavie Giustino G, Baber U, Sartori S, Aoi S, Aquino M, Chandrasekhar Jackson LR 2nd, Peterson ED, McCoy LA, Ju C, Zettler M, Baker S, Rao S, Strauss C, Baker B, Mehran R. Patterns of use of CJ, Kyritsl F, Lovic D, Karasik P, Moore H. Exercise capacity and J, Weintraub W, Rao S; Weiss S, Henry T, Kapadia S. Poddar K, BA, Messenger JC, Faries DE, Effron MB, Cohen DJ, Wang prasugrel or clopidogrel in elderly patients in the “real world” atrial fibrillation risk in veterans: a cohort study. Mayo Clin Proc DeFranco A, Muhlestein J, Toma C, Effron M, Keller S, Baker, TY. Impact of Proton Pump Inhibitor Use on the Comparative from the PROMETHEUS registry. Eur Heart J 2016; 37: (Abstract 2016 May; 91(5): 558–66. Pocock S, Mehran R. Incidence, predictors and impact of stroke Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights Supplement) 383. after percutaneous coronary intervention for acute coronary From the Treatment With Adenosine Diphosphate Receptor Federspiel JJ, Anstrom KJ, Xian Y, McCoy LA, Effron MB, syndromes: results from the PROMETHEUS registry. J Am Coll Inhibitors: Longitudinal Assessment of Treatment Patterns and Eiswirth CC. A comprehensive transition of care plan for Faries DE, Zettler M, Mauri L, Yeh RW, Peterson ED, Wang TY; Cardiol 2016; 67: 48S. Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. a patient admitted with acute decompensated heart failure Treatment With Adenosine Diphosphate Receptor Inhibitors– J Am Heart Assoc 2016;5(10). pii: e003824. in: Pharmacologic Trends of Heart Failure. Editor, Ventura HO. Longitudinal Assessment of Treatment Patterns and Events After Guazzi M, Arena R, Halle M, Piepoli MF, Myers J, Lavie CJ. 2016 Springer Publishing. 73–124, 2016. Acute Coronary Syndrome (TRANSLATE-ACS) Investigators. focused update: clinical recommendations for cardiopulmonary Jahangir E, Morin DP. From the Editor’s Desk: Ochsner Journal Comparing Inverse Probability of Treatment Weighting and exercise testing data assessment in specific patient populations. Focus Iissue: Cardiovascular Diseases. Fall; 16(3): 193, 2016. Ernstsen L, Rangul V, Nauman J, Nes BM, Dalen H, Krokstad Instrumental Variable Methods for the Evaluation of Adenosine Circulation 2016 Jun 14; 133(24): e694–711. S, Lavie CJ, Blair SN, Wisloff U. Protective effect of regular Diphosphate Receptor Inhibitors After Percutaneous Coronary Jahangir E, Polin N. Cardiac Follow-up of Cancer Survivors: physical activity on depression after myocardial infarction: Intervention. JAMA Cardiol 2016; 1(6): 655–65. Hermann HC, Thourani VH, Kodali SK, Makkar PR, Szeto Should Individuals with Prior Radiation Therapy have Routine The HUNT Study. Am J Med 2016 Jan; 129(1): 82–88. WY, Anwaruddin S, Desai N, Lim S, Malaisrie SC, Kereiakes Cardiac Stress Testing to Rule Out Coronary Artery Disease? Fosbøl EL, Ju C, Anstrom KJ, Zettler ME, Messenger JC, DJ, Ramee S, Greason KL, Kapadia S, Babaliaros V, Hahn RT, Eur Heart Journal 2016 Sep 21; 37(36): 2745–2747. Faggioni M, Chandrasekhar J, Baber U, Sartori S, Aquino M, Waksman R, Effron MB, Baker BA, Cohen DJ, Peterson ED, Pibarot P, Weissman NJ, Leipsic J, Whisenant BK, Webb JG, Rao S, Weintraub W, Effron M, Baker B, Danias G, Pocock Wang TY. Early Cessation of Adenosine Diphosphate Receptor Mack MJ, Leon MB, PARTNER Investigators. One-Year clinical Jalbert JJ, Nguyen LL, Gerhard-Herman MD, Kumamaru H, S, Kapadia S, Toma C, Mehran R, Henry T. Prevalence and Inhibitors Among Acute Myocardial Infarction Patients outcomes with SAPIEN 3 transcatheter aortic valve replacement Chen CY, Williams LA, Liu J, Rothman AT, Jaff MR, Seeger JD, outcomes of prasugrel versus clopidogrel in patients with and Treated With Percutaneous Coronary Intervention: Insights in high-risk and inoperable patients with severe aortic stenosis. Benenati JF, Schneider PA, Aronow HD, Johnston JA, Brott TG, without diabetes following percutaneous coronary intervention From the TRANSLATE-ACS Study (Treatment With Adenosine Circulation 2016; 134(2): 130–140. Tsai TT, White CJ, Setoguchi S. Comparative Effectiveness for acute coronary syndrome. Eur Heart J 2016; 37: (Abstract Diphosphate Receptor Inhibitors: Longitudinal Assessment of Carotid Artery Stenting Versus Carotid Endarterectomy Supplement) 379. of Treatment Patterns and Events After Acute Coronary Hess CN, Wang TY, McCoy LA, Messenger JC, Effron MB, Zettler Among Medicare Beneficiaries. Circ Cardiovasc Qual Syndrome). Circ Cardiovasc Interv 2016; 9(11). pii: e003602. ME, Henry TD, Peterson ED, Fonarow GC. Unplanned Inpatient Outcomes. 2016 May; 9(3): 275–85. Falck RS, Best JR, Drenowatz C, Hand GA, Shook RP, Lavie and Observation Rehospitalizations After Acute Myocardial CJ, Blair SN. Psychosocial determinants of wieght loss among Franklin BA, Berra K, Lavie CJ. Should I have an exercise stress Infarction: Insights From the Treatment With Adenosine Javed F, Ramee S. The unknown association of PPIs with chest young adults with overweight and obesity: HOW DOES DRIVE test? JAMA Cardiol 2016 Nov 2 [Epub ahead of print]. Diphosphate Receptor Inhibitors: Longitudinal Assessment of pain in patients with known, treated coronary artery disease-A FOR THINNESS AFFECT WEIGHT LOSS? J Cardiopulm Rehabil Treatment Patterns and Events After Acute Coronary Syndrome diagnostic dilemma. Curr Probl Cardiol. 2016; 31 (7–8): 235–244. Prev 2016 Oct 28 [Epub ahead of print]. Gili S, Grosso Marra W, D’Ascenzo F, Lonni E, Calcagno A, (TRANSLATE-ACS) Study. Circulation 2016; 133(5): 493–501. Cannillo M, Ballocca F, Cerrato E, Pianelli M, Barbero U, Javed, Fahad, Ramee Stephen. Proton pump inhibitors Fares H, DiNicolantonio JJ, O’Keefe JH, Lavie CJ. Amlodipine Mancone M, DiNicolantonio JJ, Lavie CJ, Omede P, Montefusco Htyte N, Gupta T, Shum K, Jacobs E, Wilson B, Avati R, and angina: A new clinical Dilemma. Current Problems in in hypertension: a first-line agent with efficacy for improving A, Bonora S, Gasparini M, Biondi-Zoccai G, Moretti C, Gaita Ahmad H, Cash M, Dinshaw H, Gilliland Y, Jahangir E, Lavie Cardiology 2016; 41 (7–9): 229–244. blood pressure and patient outcomes. Open Heart 2016 F. Comparative safety and efficacy of statins for primary C, Reilly J, Shah S. Appropriate Use of Transesophageal CARDIOVASCULAR SERVICES CARDIOVASCULAR
Sep 28; 3(2): e000473. prevention in human immunodeficiency virus-positive patients: Echocardiography and it’s Clinical Impact. Journal of Am Johannsen NM, Swift DL, Lavie CJ, Earnest CP, Blair SN, | a systematic review and meta-analysis. Eur Heart J 2016 Feb Society of Echocardiography June 2016; 29(6); B59. Church TS. Combined aerobic and resistance training effects Farhan S, Baber U, Chandrasekhar J, Sartori S, Aquino M, Giustino 6;pii:ehv734 [Epub ahead of print]. on glucose homeostasis, fitness, and other major health G, Kini A, Weintraub W, Rao S, Kapadia S, Weiss S, Strauss C, indices: a review of current guidelines. Sports Med 2016 Toma C, Muhlestein JB, DeFranco A, Effron M, Keller S, Baker Gilliland YE, Lavie CJ, Ahmad H, Bernal JA, Cash ME, Dinshaw May 3 (Epub ahed of print).
B, Pocock S, Henry T, Mehran R. Predictors of optimal medical H, Milani RV, Shah S, Bienvenu L, White CJ. Development RESEARCH therapy on discharge after percutaneous coronary intervention and implementation of a quality improvement process for for acute coronary syndrome: An analysis of the PROMETHEUS echocardiographic laboratory accreditation. Echocardiography registry. J Am Coll Cardiol 2016; 68(Suppl 1): B90. 2016 Mar; 33(3): 459–71. OCHSNER OUTCOMES
62 63 Kachur S, Menezes AR, De Schutter A, Milani RV, Lavie CJ. Krishnamoorthy A, Peterson ED, Knight JD, Anstrom KJ, Lavie CJ, De Schutter A, Parto P, Jahangir E, Kokkinos P, Lavie CJ, Wenger NK. Special patient populations: women Signifance of comorbid psychological stress and depression on Effron MB, Zettler ME, Davidson-Ray L, Baker BA, McCollam Ortega FB, Arena R, Milani RV. Obesity and prevalence of and elderly. In: Ballantyne CM, ed. Clinical Lipidology: outcomes after cardiac rehabilitation. Am J Med 2016 Jul 29 PL, Mark DB, Wang TY. How Reliable are Patient-Reported cardiovascular diseases and prognosis – the obesity paradox A Companion to Braunwald’s Heart Disease. Philadelphia, PA: pii:S0002-9343(16)30731-8/ Rehospitalizations? Implications for the Design of Future Practical updated. Prog Cardiovasc Dis 2016 Mar–Apr; 58(5): 537–47. Elsevier; 2015: 418–426. Clinical Studies. J Am Heart Assoc 2016;5(1). pii: e002695. Kachur SM, De Schutter A, Lavie CJ, Dinshaw H, Jahangir E, Lavie CJ, Forman DE, Arena R. Bulking up skeletal muscle Lavie CJ. Analyzing 2015 impact factors-special Milani R. Increased fitness modifies the obesity paradox by Larmore C, Effron MB, Molife C, DeKoven M, Zhu Y, Lu J, to improve heart failure prognosis. JACC Heart Fail 2016 Apr; editor’s commentary. Prog cardiovasc Dis 2016 Aug 28 body composition even in individuals with low cardiorespiratory Karkare S, Lieu HD, Lee WC, Vetrovec GW. “Real-World” 4(4): 274–6. pii:S0033-0620(16)30088-3. fitness. Ochsner Journal 2016; 16(3): 365. Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Lavie CJ, Harmon KG. Routine ECG screening of young Lee DC, Lavie CJ, Church TS, Sui X, Blair SN. Leisure-time Kachur SM, De Schutter A, Lavie CJ, Jahangir E, Dinshaw Intervention in the United States. Catheter Cardiovasc Interv athletes: can this strategy ever be cost effective? J Am Coll running and all-cause cancer mortality: 1874 board #26 June H, Milani R. The impact of depression, anxiety, hostility, 2016; 88(4): 535–544. Cardiol 2016 Aug 16; 68(7)L712–4. 2, 3:30 PM – 5:00 PM. Med Sci Sports Exerc 2016 May; 48, and combined psychosocial stress on mortality after cardiac 5 Suppl 1: 514. rehabilitation. Ochsner Journal 2016; 16(3): 363. Lavie C, Berger J, Foody JA, Ferdinand K. Updated ACCF/ Lavie CJ, Mehra MR, Ventura HO. Body composition and AHA Guidelines on the Management of STEMI: implications advanced heart failure therapy: weighing the options and Lee DC, Lavie CJ, Sui X, Blair SN. Running and mortality: is Kadian-Dodov D, Gornik HL, Gu X, Forehlich J, Bacharach JM, of antiplatelet therapy (Part II of II). The Medical Roundtable outcomes. JACC Heart Fail. 2016 Oct; 4(10): 769–71. more actually worse? Mayo Clin Proc 2016 Apr; 91(4): 534–6. Chi YW, Gray BH, Jaff MR, Kim ES, Mace P, Sharma A, Kline- Cardiovascular Edition, 2016. Rogers E, White CJ, Olin, JW. Dissection and Aneurysm Lavie CJ, Menezes AR, De Schutter A, Milani RV, Blumenthal Leon MB, Smith CR, Mack MJ, Shah S, et al. PARTNER in Patients With Fibromuscular Dysplasia. J Am Coll Cardiol. Lavie C, Franklin B, Mittleman M. Acute cardiac events and the JA. Impact of cardiac rehabilitation and exercise training 2 Investigators. Transcatheter or Surgical Aortic-Valve 2016; 68(2): 176–185. preventive role of regular exercise. The Medical Roundtable on psychological risk factors and subsequent prognosis Replacement in Intermediate-Risk Patients. New England Cardiovascular Edition, 2016. in patients with cardiovascular disease. Can J Cardiol 2016 Journal of Medicine 2016 Apr 28; 374(17): 1609–20. Kaminsky LA, Brubaker PH, Guazzi M, Lavie CJ, Montoye AH, Oct; 32(10S2): S365–373. Sanderson BK, Savage PD. Assessing physical activity as a core Lavie CJ, Archer E, Jahangir E. Cardiovascular health and Mandras S, Ventura HO, Corris PA. Breaking down the barriers: component in cardiac rehabilitation: a position statement of obesity in women: is cardiorespiratory fitness the answer? Lavie CJ, Parto P, Archer E. Obesity, fitness, hypertension, why the delay in referral for pulmonary arterial hypertension. the American Association of Cardiovascular and Pulmonary J Womens Health (Larchmt) 2016 Jul; 25(7): 657–8. and prognosis: is physical activity the common demonimator? The Ochsner Journal, 2016 Fall; 16(3): 210–216. Rehabilitation. J Cardiopulm Rehabil Prev 2016 Jul–Aug; JAMA Intern Med 2016 Feb; 176(2): 217–8. 36 (4): 217–29. Lavie CJ, Arena R, Blair SN. A call to increase physical activity Maurer MS, Hanno M, Grogan M, Dispenzieri A, Witteles across the globe in 21st century. Future Cardiol 2016 Nov; Lavie CJ, Sharma A, Alpert MA, De Schutter A, Lopez-Jimenez R, Drachman B, Judge DP, Lenihan DJ, Gottlieb SS, Shah SJ, Karim S, Lucas V, Verma A, Girgrah N, Ramee S, Castriota 12(6): 605–607. F, Milani RV, Ventura HO. Update on obesity and obesity Steidley DE, Ventura H, Murali S, Silver MA, Jacoby D, Fedson S, F, Micari A, Roscitano G, Spinelli F, Gafoor S, Haseeb A, paradox in heart failure. Prog Cardiovasc Dis 2016 Jan–Feb; Hummel SL, Kristen AV, Damy T, Plante-BordeneuveV, Coelho Khan A, Franke J, Matic P, Reinartz M, Bertog S, Vaskelyte L, Lavie CJ, Arena R, Franklin BA. Cardiac rehabilitation and 58(4): 393–400. T, Mundayat R, Suhr OB, Waddington Cruz M, Rapezzi C, Hofmann I, Sievert H. How should I treat Budd-Chiari syndrome healthy life-style interventions: rectifying program deficiences THAOS Investigators. Genotype and Phenotype of transthyretin after liver transplantation with inferior vena cava occlusion? to improve patient outcomes. J Am Coll Cardiol 2016 Jan 5; Lavie CJ, Ventura HO. Impact of obesity on the prevalence and cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome CARDIOVASCULAR SERVICES CARDIOVASCULAR
Eurointervention 2016; 12(1): 124–128. 67(1): 13–5. prognosis of heart failure-it is not always just black and white. Survey). J Am Coll Cardiol. 2016 July 12; 68(2): 161–72. | J Card Fail 2016 Aug; 22(8): 598–9. Kokkinos PF, Faselis C, Myers J, Narayan P, Sui X, Zhang J, Lavie Lavie CJ, Blair SN. Cardiorespiratory fitness and risk of sudden McNamara RL, Kennedy KF, Cohen DJ, Direcks DB, Moscucci CJ, Moore H, Karasik P, Fletcher R. Cardiorespiratory fitness cardiac death in men and women in the United States: a Lavie CJ, Ventura HO. Reply: The “obesity paradox” is not a M, Ramee S, Wang TY, Connolly T, Spertus JA. JACC 2016; and incidence of major adverse cardiovascular events in US prospective evaluation from the Aerobics Center Longitudinal paradox: time to focus on effective treatments. JACC Heart Fail 68(6): 626–635.
Veterans: a cohort study. Mayo Clin Proc 2016 Nov 19 [Epub Study. Mayo Clin Proc 2016 Jul; 91(7): 849–57 2016 Mar; 4(3): 234–5. RESEARCH ahead of print]. OCHSNER OUTCOMES
64 65 Mechanical Circulatory Support for the Failing Heart: Moser M, Lackland D, Black H, Basile J, Sica D, Carter B, Omran J, Abdullah O, Abu-Fadel M, Gray WA, Firwana B, Ramee SR, Anwaruddin S, Kumar G, Piana RN, Babaliaros V, Rab T, Continuous-Flow Left Ventricular Assist Devices. Englert JA 3rd, Messerli F, Rosendorff C, Nissen S, Cushman W, Berger J, Drachman DE, Mahmud E, Aronow HD, White CJ, Al-Dadah Klein LW. The rationale for performance of coronary angiography Davis JA, Krim SR. Ochsner J. 2016 Fall; 16(#) 262–9. Review. Foody AA, Ferdinand K, Lavie C. Do thiazide diuretics cause AS. Hemorrhagic and ischemic outcomes of Heparin vs. and stenting before transcatheter aortic valve replacement. JACC: PMID:27660575. diabetes? If so, is it of clinical significance? The Medical Bivalirudin in carotid artery stenting: A meta-analysis of studies. Cardiovascular Interventions 2016; 9(23): 2371–2375. Roundtable Cardiovascular Edition, 2016. Catheter Cardiovasc Interv. 2017 Mar 1; 89(4): 746–753. Menard MT, Farber A, Assmann SF, Choudhry NK, Conte MS, Randrup E, Ventura HO. The secret trip of Dr. Alton Ochsner. Creager MA, Dake MD, Jaff MR, Kaufman JA, Powell RJ, Reid Nauman J, Nes BM, Lavie CJ, Jackson AS, Sui X, Coombes JS, Ortega FB, Lavie CJ, Blair SN. Obesity and cardiovascular Ochsner Journal, 2016. DM, Siami FS, Sopko G, White CJ, Rosenfield K. Design and Blair SN, Wisloff U. Prediction of cardiovascular mortality by diseases. Circ Res 2016 May 27; 118(11) 1752–70. Rationale of the Best Endovascular Versus Best Surgical Therapy estimated cardiorespiratory fitness independent of traditional Reilly JP, White CJ Renal Denervation for Resistant Hypertension. for Patients With Critical Limb Ischemia (BEST-CLI) Trial. J Am risk factors: the HUNT Study. Mayo Clin Proc 2016 Nov 16 Ortega FB, Sui X, Lavie CJ, Blair SN. Body mass index, Prog Cardiovasc Dis. 2016 Nov – Dec; 59(3): 295–302. Heart Assoc. 2016 Jul 8; 5(7). {Epub ahead of print]. the most widely used but also widely criticized index: would a criterion standard measure of total body fat be a better Ricketts TA, Sui X, Lavie CJ, Blair SN, Ross R. Addition of Menezes A, Krim SR, Ventura HO. The established therapies: Nes BM, Gutvik CR, Lavie CJ, Nauman J, Wisloff U. Personalized predictor of cardiovascular disease mortality? Mayo Clin Proc cardiorespiratory fitness within an obesity risk classification HF-PEF and HF-REF in: Pharmacologic Trends of Heart Failure. activity intelligence (PAI) for prevention of cardiovascular disease 2016 Apr; 91(4): 443–55. model identified men at increased risk of all-cause mortality. Editor, Ventura HO. Springer Publishing. 1–27, 2016. and promotion of physical activity. Am J Med 2016 Oct 28 [Epub Am J Med 2016 May; 129(5): 536.e13–20. ahead of print]. Papanagiotou P, White CJ. Endovascular Reperfusion Strategies for Milani RV, Bober RM, Lavie CJ. The role of technology in chronic Acute Stroke. JACC Cardiovasc Interv. 2016 Feb 22; 9(4): 307–17. Rogers PA, Morin DP. MADIT-CRT and his many sons. Trends disease care. Prog Cardiovasc Dis 2016 May–Jun; 58(6): 579–83. O’Keefe EL, DiNicolantonio JJ, Patil H, Helzberg JH, Lavie CJ. Cardiovasc Dis. Feb 26(2): 147–9, 2016. Lefestyle choices fuel epidemics of diabetes and cardiovascular Parto P, Lavie CJ, Arena R, Bond S, Popovic D, Ventura HO. Milani RV, Lavie CJ, Bober RM, Milani AR, Ventura HJ. Improving disease among Asian Indians. Prog Cardiovasc Dis 2016 Body habitus in heart failure: understanding the mechanisms Rosenthal TM, Leung ST, Ahmad R, Young T, Lavie CJ, hypertension control and patient engagement using digital tools. Mar–Apr; 58(5): 505–13. and clinical significance of the obesity paradox. Future Cardiol Moodie DS, Shah S. Lifestyle modification for the prevention Am J Med 2016 Aug 30 pii:S0002-9343(16)30844-0. 2016 Nov; 12(6): 639–653. of morbidity and mortality in adult congenital heart disease. Oktay AA, Lavie CJ, Milani RV, Ventura HO, Gilliland E, Shah Congenit Heart Dis 2016 Mar–Apr; 11(2): 189–98. Milani RV, Lavie CJ, Wilt JK, Bober RM, Ventura HO. New concepts S, Cash ME. Current perspectives on left ventiruclar geometry Parto P, O’Keefe JH, Lavie CJ. The exercise rehabilitation paradox: in hypertension management: a population-based perspective. in systemic hypertension. Prog Cardiovasc Dis. 2016 Nov–Dec; less may be more? Ochsner J 2016 Fall; 16(3); 297–303. Rosenthal TM, Masvidal D, Abi Samra FM, Bernard ML, Khatib Prog Cardiovasc Dis 2016 Nov–Dec; 59(3): 289–294. 59(3): 235–246. S, Polin GM, Rogers PA, Bober R, Morin DP: In Nonischemic Povsic TJ, Henry TD, Traverse JH, Fortuin FD, Schaer GL, Kereiakes Cardiomyopathy, Positron Emission Tomography Stress Moholdt T, Lavie CJ, Nauman J. Physical activity, body mass Oleck S, Ventura HO. Coenzyme Q10 and utility in heart failure: DJ, Schatz RA, Zeiher AM, White CJ, Stewart DJ, Jolicoeur EM, Myocardial Blood Flow Predicts Ventricular Tachyarrhythmia. index, and mortality among subjects with coronary heart just another supplement? Curr Heart Fail Rep 2016 13: 190–195. Bass T, Henderson DA, Dignacco P, Gu Z, Al-Khalidi HR, Junge Abstract, Heart Rhythm Scientific Sessions, May 10–13, 2017. disease: data from the NORD-TRONDELAG HEALTH STUDY. C, Nada A, Hunt AS, Losordo DW; RENEW Investigators. The European Medical Journal – Cardiology 2016 October; 61–62. Olin JW, White CJ, Armstrong EJ, Kadian-Dodov D, Hiatt WR. RENEW Trial: Efficacy and Safety of Intramyocardial Autologous Rosenthal TM, Masvidal D, Abi Samra FM, Bernard ML, Khatib Peripheral Artery Disease: Evolving Role of Exercise, Medical CD34(+) Cell Administration in Patients With Refractory Angina. S, Polin GM, Rogers PA, Xue JQ, Morin DP: Optimal Method of Morin DM, Bernard ML, Madias C, Rogers PA, Thihalolipavan S, Therapy, and Endovascular Options. J Am Coll Cardiol. 2016 JACC Cardiovasc Interv. 2016 Aug 8; 9(15): 1576–85. Measuring the T-peak to T-end Interval for Risk Stratification in CARDIOVASCULAR SERVICES CARDIOVASCULAR
Estes NA III. The State of the Art: Atrial Fibrillation Epidemiology, Mar. 22; 67(11): 1338–57. primary Prevention. 2016. | Prevention, and Treatment. Mayo Clin Proc: Dec; 91(12): Prasad VK, Drenowatz C, Hand GA, Lavie CJ, Sui X, Demello 1778–1810, 2016. Olin JW, White CJ, Armstrong EJ, Kadian-Dodov D, Hiatt WR. M, Blair SN. Relation of body’s lean mass, fat mass, and body Rosenthal TM, Rogers PA, Thihalolipavan S, Abi Samra FM, Reply: Endovascular-First Treatment of Peripheral Arterial mass index with submaximal systolic blood pressure in young Bernard ML, Khatib S, Polin GM,Jahangir E, Bober RM, Morin Morin DP, Lavie CJ. The many faces of sudden death. Mayo Clin Disease Remains Controversial. J Am Coll Cardiol. 2016 Sep 27; adult men. Am J Cardiol 2016 Feb 1; 117(3): 394–8. DP. Positron emission tomography stress myocardial blood flow
Proc 2016 Oct 8 [Epub ahead of print]. 68(13): 1493. predicts ventricular tachyarrhythmia in primary prevention ICD RESEARCH patients. Heart Rhythm 2016;13(5, Suppl.):S146. Featured poster presentation, Heart Rhythm Society Scientific Sessions, 2016. OCHSNER OUTCOMES
66 67 Rosenthal TM, Stahls PF III, Abi-Samra FM, Bernard ML, Khatib Sharma A, Bax JJ, Vallakati A, Goel S, Lavie CJ, Garg A, Shishehbor MH, White CJ, Gray BH, Menard MT, Lookstein Ventura HO, Lavie CJ. Tackling cardiovascular disease in Hispanic/ S, Polin GM, Xue JQ, Morin DP. Effect of heart rate correction Mukherjee D, Lichstein E, Lazar JM. Effect of cardiac R, Rosenfield K, Jaff MR. Critical Limb Ischemia: An Expert Latinos: achieving 2020 goals. Am Heart J 2016 Jun; 176: 125–6. on the T-peak to T end interval’s risk stratification ability. resynchronization therapy on right ventricular function. Statement. J Am Coll Cardiol. 2016 Nov 1; 68(18): 2002–2015. Presented at Heart Rhythm 2016. Poster Session IV. Poster Int J Cardiol 2016 Apr 15; 209: 34–6. Ventura HO. Cosas del Corazon. Semana News (weekly Spanish #205, 2016. Shum K, Solivan A, Parto P, Polin N, Jahangir E. Cardiovascular Risk newspaper, Houston, TX) February 2016. Sharma A, Bax JJ, Vallakati A, Goel S, Lavie CJ, Kassotis J, and Level of Statin Use Among Women with Breast Cancer in a Ross R, Blair SN, Arena R et al. Importance of assessing Mukherjee D, Einstein A, Warrier N, Lazar JM. Meta-analysis Cardio-Oncology Clinic. Ochsner Journal 2016 Fall; 16(3): 217–24. Vogel B, Baber U, Sartori S, Chandrasekhar J, Aquino M, Farhan cardiorespiratory fitness in clinical practice: a case for fitness as a of the relation of baseline right ventricular function to response F, Kini A, Weintraub W, Rao S, Kapadia S, Weiss S, Strauss clinical vital sign: a scientific statement from the American Heart to cardiac resynchronization therapy. Am J Cardiol 2016 Stewart MH, Jenkins S. The evolving role of percutaneous C, Toma C, Muhlestein JB, DeFranco A, Effron M, Keller S, Association. Circulation 2016 Dec 13; 134(24): e653–e699. Apr 15; 117(8): 1315–21. mitral valve repair. Ochsner Journal 2016; 16(3): 270–276. Baker B, Pocock S, Henry T, Mehran R. Sex-related differences in outcomes after percutaneous coronary intervention (PCI) Sagner M, Binks M, Yapijakis C, Lavie CJ, Frank E, Franklin Sharma A, Helft G, Garg A, Agrawal S, Chatterjee S, Lavie Sui X, Sarzynski MA, Lee DC, Lavie CJ, Zhang J, Kokkinos PF, in patients with diabetes presenting with acute coronary BA, Forman DE, Arena R, La Vecchia C, Puska P. Overcoming CJ, Goel S, Mukherjee D, Marmur JD. Safety and efficacy of Payne J, Blair SN. Longitudinal patterns of cardiorespiratory syndrome (ACS): Results from the PROMETHEUS study. J Am potential threats to schientific advancements: conflict of vorapaxar in secondary prevention of atheroslcerotic disease: fitness predict the development of hypertension among men Coll Cardiol 2016; 68(Suppl 1): B110–B111. interest, ulterior motives, false innuendos and harassment. Prog a meta-analysis of randomized control trials. Int J Cardiol. and women. Am J Med 2016 Dec 13 [Epub ahead of print]. Cardiovasc Dis 2016 Jul 19 pii:S0033-0620(16)30055-X. 2017 Jan 15; 227: 617–624. Vora AN, Peterson ED, McCoy LA, Effron MB, Anstrom KJ, Swift DL, Johannsen NM, Lavie CJ, Earnest CP, Blair SN, Church Faries DE, Zettler ME, Fonarow GC, Baker BA, Stone GW, Wang Sagner M, McNeil A, Puska P, Auffray C, Price ND, Hood Sharma A, Lavie CJ, Helft G, Chatterjee S, Goel S, Garg A, TS. Effects of clinically significant weight loss with exercise TY. Factors Associated With Initial Prasugrel Versus Clopidogrel L, Lavie CJ, Han ZG, Chen Z, Brahmachari SK, McEwen BS, Mukherjee D, Marmur JD. Role of Vorapaxar after coronary training on insulin resistance and cardiometabolic adaptations. Selection for Patients With Acute Myocardial Infarction Soares MB, Balling R, Epel E, Arena R. The P4 health spectrum revascularization. Am J Cardiol 2016 Apr 1; 117(7): 1059–64. Obesity (Silver Spring) 2016 Apr; 24(4): 812–9. Undergoing Percutaneous Coronary Intervention: Insights – a predictive, preventive, personalized and participatory From the Treatment With ADP Receptor Inhibitors: Longitudinal continuum for promoting healthspan. Prog Cardiovasc Dis 2016 Sharma A, Lavie CJ, Sharma SK, Garg A, Vallakati A, Mukherjee Syed Rashid Z, Cox-Alomar Pedro, Bohorquez Humberto, Assessment of Treatment Patterns and Events After Acute Aug 18 pii:S0033-0620(16)30078-0. D, Marmur JD. Duration of dual antiplatelet therapy after Therapondos George, Girgrah Nigel, Joshi Shobha, Tyson Coronary Syndrome (TRANSLATE-ACS) Study. J Am Heart durg-eluting stent implantation in patients with and without Gia, Reichman Trevor, Carmody Ian, Loss George, Cohen Ari, Assoc 2016; 5(9). pii: e003946. Salianski O, Baber U, Sartori S, Aoi S, Aquino M, Chandrasekhar acute coronary syndrome: a systematic review of randomized Bruce David, Ahmed Emily, Seal John, Parrino Patrick E, Ramee J, Kini A, Rao S, Weintraub W, Weiss S, Henry T, Kapadia S, controlled trials. Mayo Clin Proc 2016 Aug; 91(8): 1084–93. Stephen, Bzowej Natalie. Transcatheter aortic valve replacement Wayangankar SA, Baber U, Poddar K, Weiss S, Henry T, Poddar K, DeFranco A, Muhlestein J, Toma C, Strauss C, Effron for severe aortic stenosis as a bridge to liver transplantation. Muhlestein J, Baker B, Mehran R, Kini A, Sartori S, Rao S, M, Keller S, Baker B, Pocock S, Mehran R. Use of clopidogrel Sharma A, Lavie CJ, Vallakati A, Garg A, Goel S, Lazar J, Ochsner’s Thirteenth Annual Research Day 2016. Weintraub W, Strauss C, DeFranco A, Toma C, Keller S, Effron versus prasugrel in patients undergoing percutaneous coronary Fonarow G. Changes in various parameters of right ventricular M, Kapadia S. Predictors of 1 year net adverse cardiovascular intervention: factors influencing real-world therapeutic decision- function with cardiac resynchronization therapy. 2016. Tafur JD, Ventura HO. Bidirectional impact of two chronic events (NACE) among ACS patients undergoing PCI with making. J Am Coll Cardiol 2016; 67: 184S. diseases: heart failure and diabetes mellitus. Medwave 2016 clopidogrel or prasugrel: analysis from the PROMETHEUS Sharma A, Sharma SK, Vallakati A, Garg A, Lavie CJ, Mukherjee Dec 27; 16(Suppl4): e6823. registry. J Am Coll Cardiol 2016; 67: 562 S. Sardar P, Kundu A, Chatterjee S, Nohria A, Nairooz R, D, Marmur JD. Duration of dual antiplatelet therapy after CARDIOVASCULAR SERVICES CARDIOVASCULAR
Bangalore S, Mukherjee D, Aronow WS, Lavie C. Long-term various drug-eluting stent implantation. Int J Cardiol 2016 Turi BC, Codogno JS, Fernandes RA, Sui X, Lavie CJ, Blair SN, White CJ, Reilly JP “Won’t Get Fooled Again.” JACC Cardiovasc | cardiovascular mortality after radiotherapy for breast cancer: Jul 15; 215: 157–66. Monteiro HL. Association of different physical activity domains Interv. 2016 Jun 27; 9(12): 1300–1. a systematic review and meta-analysis. Clinical Cardiology on all-cause mortality ion adults participating in primary care in 2016; DOI 10.1002/clc.22631. Sheikh AB, Felzer JR, Munir AB, Morin DP, Lavie CJ. Evaluating the Brazilian National Health System: 4-year follow-up. J Phys Wissam A J, Fong PP, Giora W, Omar L, Jenkins J, Rosenfield K, the benefits of home-based management of atrial fibrillation: Act Health 2016 Oct 24: 1–22. Rab T, Ramee S. Acute pulmonary embolism with an emphasis
Shah SB, Gupta T, Severinsen KD, McIlwain E, White CJ. current perspectives. Pragmat Obs Res 2016 Oct 13; 7: 41–53. on an interventional approach. JACC 2016; 67(8): 991–1002. RESEARCH Volume to Value: Defining the Value of Cardiovascular Imaging. Ventura HO, Lavie CJ. Impact of comorbidities in hypertension. Ochsner J. 2016 Fall; 16(3): 203–7. Curr Opin Cardiol 2016 Jul; 31(4): 374–5. OCHSNER OUTCOMES
68 69 Physician Team Contact Information and Locations
Ochsner Medical Center – Interventional Cardiology Ochsner Medical Center – Baton Rouge Ochsner Health Center – Sherwood Kenner New Orleans John Reilly, MD North Shore Ochsner Medical Center – 170 McGehee Dr. Ochsner Medical Center – Kenner Section Head, Interventional Cardiology Michael Bennett, MD Baton Rouge Baton Rouge, LA 70815 180 W. Esplanade Ave. Consultative Cardiology Vice Chairman, Clinical Affairs, Abhijit Ghatak, MD 17000 Medical Center Dr. 225.761.5200 Kenner, LA 70065 Patrick Breaux, MD Department of Cardiovascular Disease James Lam, MD Baton Rouge, LA 70816 504.464.8600 Section Head, Consultative Cardiology Director , Cardiovascular CT Glenn Polin, MD 225.752.2470 Ochsner Health Center – Medical Director, Cardiac Step- Program Director, Interventional Summa (Bluebonnet Boulevard) Ochsner Health Center – Kenner Down Unit Cardiology Fellowship Program Ochsner Medical Center – Ochsner Health Center – Hammond 9001 Summa Ave. 200 West Esplanade Ave., Suite 205 Maurizio Capogrossi, MD Tyrone Collins, MD West Bank Campus 16045 Doctors Blvd. Baton Rouge, LA 70809 Kenner, LA 70065 Christopher Damm, MD J. Stephen Jenkins, MD Samuel Ferris, MD Hammond, LA 70403 225.761.5200 504.464.8588 Mark Effron, MD Rajan Patel, MD Sanjay Dravid, MD 985.543.3664 David Elizardi, MD Stephen Ramee, MD Michael Castine, MD Greater New Orleans Ochsner Health Center – St. James Guergana Enikova, MD Jose Tafur, MD Ochsner Medical Complex – Iberville Ochsner Medical Center 1645 Lutcher Ave. Gary Rich, MD Christopher White, MD Ochsner Medical Center – 25455 Hwy. 1 1514 Jefferson Hwy. Lutcher, LA 70071 Nichole Polin, MD Kenner Plaquemine, LA 70764 New Orleans, LA 70121 225.258.2037 Noninvasive Cardiology Jonathan Bonilla, MD 225.761.5200 504.842.4135 or 866.Ochsner Advanced Heart Failure/Transplant Michael Cash, MD Nakash Grant, MD Ochsner Health Center – Hector Ventura, MD Section Head, Non-Invasive Zola N’dandu, MD Ochsner Health Center – Central Ochsner Health Center – Mid-City LaPlace Medical Section Head, Advanced Heart Failure/ Cardiovascular Imaging Benjamin Romick, MD 11424-2 Sullivan Rd. 411 N. Carrollton Ave., Suite 4 735 W. 5th St. Transplantation J. Alberto Bernal, MD Central, LA 70818 New Orleans, LA 70119 LaPlace, LA 70068 John Biglane, MD Robert Bober, MD Ochsner Medical Center – 225.261.9790 504.842.4135 or 866.Ochsner 985.224.1248 Sapna Desai, MD Homeyar Dinshaw, MD Baton Rouge Hamang Patel, MD Yvonne Gilliland, MD Brian Jones, MD Ochsner Health Center – Ochsner Health Center – Metairie West Bank
Stacy Mandras, MD Carl “Chip” Lavie, MD Bahij Khuri, MD Denham Springs South 2005 Veterans Memorial Blvd. Ochsner Health Center – Lapalco CONTACT INFORMATION AND LOCATIONS Clem Eiswirth, MD Richard Milani, MD Pavan Malur, MD 139 Veterans Blvd. Metairie, LA 70002 4225 Lapalco Blvd. Selim Krim, MD Salima Qamruddin, MD Douglas Mendoza, MD Denham Springs, LA 70726 504.842.4168 Marrero, LA 70072 Sangeeta Shah, MD Salvador Velazquez, MD 225.761.5200 504.595.8119 Electrophysiology Zee Zheng, MD North Shore Sammy Khatib, MD Ochsner Health Center – Michael Bernard, MD Ochsner Health Center – O’Neal Ochsner Health Center – Covington Ochsner Medical Center – CARDIOVASCULAR SERVICES CARDIOVASCULAR
Vice Chairman, Department Covington Freddy Abi-Samra, MD 16777 Medical Center Dr. 1000 Ochsner Blvd. West Bank Campus | of Cardiology Ali Amkieh, MD Baton Rouge, LA 70816 Covington, LA 70433 2500 Belle Chasse Hwy. Section Head, Electrophysiology Gerardo Aristimuno, MD 225.754.3278 985.875.2828 Gretna, LA 70056 Program Director, Clinical Cardiac Patrick Delaney, MD 504.371.9355 Electrophysiology George Isa, MD Ochsner Health Center – Prairieville Ochsner Specialty Health Center One – Freddy Abi-Samra, MD Michael Lecce, MD 16220 Airline Hwy. Slidell For patient referral Daniel Morin, MD Sammy Khatib, MD Prairieville, LA 70769 1850 E. Gause Blvd. Glenn Polin, MD Leonardo Orejarena, MD 225.744.1111 Slidell, LA 70461 and transfer information, Michael Bernard, MD 985.639.3777 please see page 72. OCHSNER OUTCOMES Paul Rogers, MD 70 71 About Ochsner Health System
Ochsner Health System is Louisiana’s largest non-profit, academic healthcare system. Driven by a mission to Serve, Heal, Lead, Educate and Innovate, coordinated clinical and hospital patient care is provided across the region by Ochsner’s 29 owned, managed and affiliated hospitals and more than 80 health centers and urgent care centers. Ochsner is the only Louisiana hospital recognized by U.S. News & World Report as a “Best Hospital” across four specialty categories caring for patients from all 50 states and more than 80 countries worldwide each year. Ochsner employs more than 18,000 employees and over 1,100 physicians in over 90 medical specialties and subspecialties, and conducts more than 600 clinical research studies. Ochsner Health System is proud to be a tobacco-free environment. For more information, please visit ochsner.org and follow us on Twitter and Facebook.
Patient referrals, transfers and consults are critically important. We make it easy Visit us online at ochsner.org for referring providers and their staff. To refer your patient for a clinic appointment, call our Clinic Concierge at 855.312.4190. To initiate a transfer to any Ochsner hospital, call our Regional Referral Center, staffed 24/7 by clinicians, at 855.OHS.LINK (647.5465).
For patients needing to schedule their own appointments, please call 866.OCHSNER (624.7637). CARDIOVASCULAR SERVICES CARDIOVASCULAR
| OUTCOMES OCHSNER
72 OCHSNER.ORG